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Summary.
Three HAT-sensitve ce l l  l ines were examined for  
t h e i r  s u i t a b i l i t y  in producing human monoclonal 
antibodies (MCA) by fusion with peripheral  blood 
lymphocytes (PBL). The human ce l l  l i n e  LICR-L0N-HMy2 
(HMy2) was found to generate hybrids with too low an 
e f f i c ie n c y  to be useful .  Two mouse myeloma ce l l  l i n e s ,
N S 1 / I . Ag4.1 ( NS1) and X63-Ag8.653 (X63) both fused with 
high e f f i c i e n c i e s .  X63 was selected for  intensive study 
on the basis of a higher fusion frequency, and lack of  
production of mouse immunoglobulin. This l i n e  proved to 
be an exce l len t  fusion par tner .  Hybrids were formed, from 
both normal and autoimmune pat ien ts ,  which supported the 
secret ion of useful amounts of human immunoglobulins M, G 
and A of both kappa and lambda isotypes.The hybrids were 
robust in cul ture ,  cloned e f f i c i e n t l y  and were eas i l y  
recovered from storage in l i q u i d  ni t rogen.  Hybrid 
i n s t a b i l i t y  was not a problem. Of th i r te e n  hybrids 
selected for  intensive study, twelve were successful ly  
cloned and continued immunoglobulin secret ion through a 
period of observation of six to e ight  months in 
continuous cul ture .  Two fusions were performed with X63 
and PBL transformed by Epstein-Barr  vi rus (EBV) and one 
fusion with tonsi l  c e l l s  transformed by EBV. Both the 
fusion frequency and proport ion of hybrids secret ing  
human immunoglobulins were increased in fusions with EBV 
transformed c e l l s .  I t  is concluded tha t  EBV
transformat ion followed by fusion with X63 represents a 
highly e f f i c i e n t  method of producing human MCA.
The p o s s i b i l i t y  of producing human monoclonal 
autoantibodies was invest igated by fusing PBL from 
pat ients with myasthenia gravis (MG) or systemic lupus 
erythematosus (SLE). Al l  MG pat ients had demonstrable 
serum autoantibodies to the acety lchol ine  receptor  
(AChR). The SLE pat ients were selected for  high serum 
autoantibody t i t r e s  to Ro, La or nRNP. Ten fusions with 
MG PBL y ie lded 459 human immunoglobulin-secreting 
hybrids.  No antibody a c t i v i t y  to the AChR was detected by 
RIA in any of the supernatants.  Twelve fusions with SLE 
PBL y ie lded 220 human immunoglobulin-secreting hybrids.
No MCA were detected by ELISA which reacted s p e c i f i c a l l y  
with e i t h e r  Ro, La, nRNP or DNA. When these MCA were 
screened by i n d i r e c t  immunofluorescence against  f ixed  
human c e l l s ,  two gave even cytoplasmic sta in ing pat terns,  
and twelve stained cytoplasmic f i l aments.  The f i laments  
recognised were character ised as being intermediate  
f i laments .  In addi t ion to binding intermediate f i laments,  
one MCA was found to react  with microf i laments.  When MCA 
derived from other sources were screened against  f ixed  
c e l l s ,  s i m i l a r  high proportions were found with 
a n t i - in te r m e d ia te  f i l ament  a c t i v i t y .  MCA to intermediate  
f i laments were found in hybrids derived from 
EBV-transformed tonsi l  ce l ls  ( 3 / 4 8 ) ,  normal PBL ( 3 / 5 4 ) ,  
EBV transformed PBL (5/80)  and MG PBL ( 3 / 6 5 ) .  In addit ion  
to binding intermediate f i l aments,  one MCA from a
myasthenic p a t ie n t  also reacted with DNA. MCA to 
intermediate f i laments are thus not re lated to the 
autoimmune status of the donors, and may not represent  
conventional ant i  body-ant i  gen in t e ra c t i o n s .  The high 
proportion of MCA to intermediate f i laments may be 
related to the frequent  occurrence of serum ant ibodies  
with this r e a c t i v i t y  in a number of d i f f e r e n t  autoimmune 
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Abbrevi a t i  ons.
Ab : Anti body( ies)
AChR : Acetylchol ine receptor
AET : 2-ami noethyl isothiouroniurn bromide hydrobromide 
Ag : Antigen
Alpha-BTX : Alpha bungarotoxin 
ALD : Alcohol ic l i v e r  disease 
ANA : Ant i -nuc lear  ant i  body( i e s )
APC : Antigen presenting ce l l
BSA : Bovine serum albumin
CAH : Chronic ac t ive  he p a t i t i s
CCL : Chronic lymphocytic leukaemia
CELIA : Competit ive enzyme l inked immunosorbent assay
DMSO : Dimethyl sulphoxide
DNA : Deoxyribonucleic acid
DNAse : Deoxyribonuc1 ease
EAMG : Experimental ly acquired myasthenia gravis
EBV : Epstein-Barr  v i rus
EDTA : E thy lened iaminetet ra -acet ic  acid
EGTA : E t h y l e n e g ly c o l - b i s - ( Beta-amino-ehyl ether)
N,N1- t e t r a - a c e t i c  acid 
ELISA : Enzyme l inked immunosorbent assay 
FCS : Foetal c a l f  serum
HAT : Hypoxanthine, aminopterine and thymidine 
HT : Hypoxanthine and thymidine 
Ig : Immunoglobulin(s)
LPS : Lipopolysaccharide
MCA : Monoclonal ant ibody( i e s )
MCTD : Mixed connective t issue disease 
MHC : Major h is toc om pa t ib i l i ty  complex 
Mr : Relat ive  molecular mass 
NCS : Newborn c a l f  serum 
NP40 : Nonidet P-40
PAGE : Polyacrylamide gel e lectrophoresis
PEG : Polyethylene glycol
PBC : Primary b i l i a r y  c i r rho s is
PBL : Peripheral  blood lymphocytes
PBS : Phosphate buffered sal ine
PMSF : Phenyl methane sulphonyl f lu or id e
PWM : Pokeweed mitogen
RA : Rheumatoid a r t h r i t i s
RF : Rheumatoid fa c t o r
RIA : Radioimmunoassay
RNA : Ribonucleic acid
SD : Standard deviat ion
SDS : Sodium dodecyl sulphate
SLE : Systemic lupus erythematosus
SRBC : Sheep red blood ce l l s
SS : Sjogren's syndrome
UY : U l t r a - v i o l e t
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It has been widely held for many years that the 
function of the immune system is primarily, if not 
entirely concerned with the protection of the individual 
against infectious agents. Ehrlich*s famous phrase horror 
autotoxicus, expressing the idea that self-reactivity is 
an abnormal and pathological condition, has long been a 
pervasive influence in immunology. Hand in hand with this 
notion, the question of: why an animal does not normally 
make deleterious responses to its own antigens, has been 
a central question. The first serious attempt to explain 
how self unresponsiveness might be acquired was put 
forward by Burnet as a corollary to his clonal selection 
theory. This hypothesis postulates that each clone of 
lymphocytes gives rise to cells making antibody of only 
one specificity. Lymphocytes of a particular clone 
respond to contact with the corresponding antigen by 
proliferation and differentiation into plasma cells. 
Burnet also suggested that antibody diversity is 
generated by rapid somatic mutation, especially in 
embryonic development. Since some of these randomly 
generated clones would be likely to react with 
self-antigens, he suggested that these would be 
eliminated if they came into contact with the 
corresponding autoantigen during the critical period of 
development. Thus self-reactive lymphocytes would be 
selectively deleted (Burnet and Fenner 1949). This would 
predict that if animals were exposed to foreign antigens 
during the critical period, they would be tolerant to
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them in adult life. This indeed was confirmed 
experimentally by Medawar and his colleagues (Billingham 
et a l . 1953/1956). Animals injected at birth with either 
allogenic tissue or heterologous protein antigens were 
unable to reject allogenic skin grafts/ or make 
antibodies to the proteins later in life. Within a few 
years numerous reports of tolerance induction to a 
variety of antigens appeared (Hanan and Oyama 1954/ Dixon 
and Maurer 1955/ Simonsen 1955/ Weigle and Dixon 1959/ 
Smith and Bridges 1958). In general/ large doses of the 
foreign protein were employed and it was found easier to 
induce tolerance in immature rather than mature animals. 
Lower doses of antigens were found to be required for 
tolerance induction in young animals/ and tolerance was 
both more profound and of longer duration.
In its simplest form however/ the clonal 
deletion hypothesis explaning natural self-tolerance is 
no longer considered tenable. With the weight of 
considerable experimental evidence/ self-reactivity is 
now believed to be a normal feature of the immune system. 
It is convenient to consider this evidence in relation to 
Talal's (1977) suggested three stages of response to 




This describes the role of self-recognition in 
the normal functioning of the immune system. It includes 
the fundamental principles facilitating regulatory 
interactions of the cells of the immune system. The 
binding of antigen to receptors on B cells does not 
usually result in the triggering of B cells unless a 
helper T cell also recognises the antigen. In addition to 
recognising the antigen, helper T cells appear to promote 
B cell differentiation only if certain antigenic 
determinants on the B cell surface are complementary to 
receptors on the T cell. These cell surface antigens and 
receptors are determined by the major histocompatibility 
complex (M H C ). Within the MHC lies a locus of genes which 
influence the immune response (the immune response or Ir 
genes); this expresses itself on the surface of cells of 
the immune system as class II antigens (la antigens in 
mice, HLA-D antigens in humans). Recognition of class II 
antigens by helper T cells appears to be nearly always 
necessary in T cell antigen dependent differentiation of 
B cells.
Antibodies or T cell factors directed against 
the individuals own receptors are the essential 
ingredients in the network theory of immune regulation 
proposed by Jerne (1973,1974a,1974b) and extended by 
others (Kohler 1975, Richter 1975, Hoffman 1975). This 
theory attempts to explain the behaviour of the immune
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system by the interactions of antigens, idiotypes and 
anti-idiotypes. The configuration of every 
antigen-binding receptor, or idiotype, allows interaction 
with either of two structurally complementary substances. 
One is the specific antigen, and the other is the 
receptor of another clone of lymphocytes, the 
anti-idiotype. The idiotypes and anti-idiotypes may 
reside on either T or B cells and their antigen binding 
products (antibodies or T factors). The anti-idiotypes 
themselves can also recognise structurally complementary 
antigens, and be recognised in turn by other receptors, 
anti-anti-idiotypes. The whole immunological web is thus 
seen as mutually interacting and self regulating. The 
network theory has received some experimental support. 
Spontaneous synthesis of anti-idiotype antibody has been 
detected during immunisation of an animal to a particular 
antigen (Kluskens and Kohler 1974).Injection of 
anti-idiotype antibodies has been shown to suppress the 
particular T and B cells bearing the idiotype (Nisonoff 
and Bangasser 1975). Under certain circumstances, 
anti-idiotype antibodies have been shown to trigger 
lymphocytes (Trenker and Riblet 1975).
The state of auto-recognition includes Grabar's 
(1983) interpretation of the immune system's 
physiological function, where immunoglobulins are seen as 
transporters of catabolic materials. This is one 
interpretation of numerous experiments which have 
provided ample evidence that autoantibodies and the B
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cells which produce them are a ubiquitous feature of the 
immune system. Studies with radiolabelled autoantigens/ 
for example thyroglobin, have shown that autoantigen 
binding B lymphocytes are present normally in the blood 
of healthy subjects (Roberts ej: a_l. 1973). Normal B cell 
populations can be triggered to produce autoantibodies 
against virtually all self-constituents with appropriate 
immunisation or stimulation (Elson et ajL. 1979). 
Polyclonal B cell mitogens such as LPS, when injected 
into normal mice have been shown to induce serum 
autoantibodies to IgG (Dresser 1976, 1978, Izui eit a l . 
1979a), DNA (Fourney et al_. 1974, Izui et a_l. 1979b), 
erythrocytes (Cunningham 1974), and thymocytes (Izui 
et a l . 1979b). An extremely high proportion (75%) of 
lymphocytes stimulated to immunoglobulin secretion by LPS 
in vitro produce autoantibodies (Dziarski 1982a). The 
LPS-induced autoimmune state jLn vivo is self-limiting, 
and the autoantibodies disappear within a short time 
after the LPS injection (Dziarski 1982b).
In addition to evidence for the existence of B 
cells capable of producing autoantibodies, sensitive 
methods of detection indicate that autoantibodies against 
a large number of self-antigens are found naturally in 
the serum of normal, healthy individuals. Darr and Fabre 
(1981) developed a highly sensitive binding immunoassay, 
depending on exposing 25 yl of serum for 1 hr on ice to 25 
yl of a suspension of homogenised brain, liver or heart. 
After washing, the homogenate was then incubated with
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radiolabelled rabbit anti-human F C a b ^  antibody. Every 
human serum examined was found to react with the 3 
homogenates. The autoantibodies were found to be IgM in 
class/ were largely human tissue specific and were found 
in all age groups from 2 to 84 years. Dighiero and 
Aureamas (1982a/ 1982b) studied 9 common autoantigens; 
tubulin/ actin/ thyroglobulin/ myoglobin/ fetuin/ 
transferrin/ albumin/ cytochrome and collagen. 
Immunoabsorbent columns were made by coupling each 
antigen to glutaraldehyde-activated, polyacrylamide gels. 
Pooled sera from 800 normal donors and three individual 
donors were passed through the columns and the retained 
protein eluted using acid. The recovered immunoglobulin 
was then tested by ELISA against the appropriate antigen. 
The results showed that both the pooled and individual 
sera contained antibody activity which was specific for 
each of the antigens tested/ the three major isotypes 
were represented/ that IgG was most abundant and that 
binding was mediated by the Fab fragment. The authors 
also examined 61 monoclonal paraproteins from human sera. 
Four had autoantibody activity against actin and 1 
against tubulin. Autoantibodies in normal sera have been 
also found to spermine (Bartos et: al^ . 1980)/ and myelin 




This state is characterised by enhanced 
autoreactions concomitant to non-self reactions such as 
in infectious disease and injury. The autoimmune state# 
like the disturbing influence# is only temporary and the 
immunological network is fundamentally intact. Several 
mechanisms may be operating to induce autoimmunity in 
infectious disease. During the course of infection# 
tissues may be damaged and release antigens. The 
autoimmune response may be merely a physiological 
mechanism for removing these products. Alternatively a 
self antigen may be modified e.g. by proteolytic enzymes# 
to such an extent that it is not recognised as self and 
initiates an immune response. Another possible mechanism 
may be termed bacterial mimicry. Several lines of 
evidence suggest that certain infectious agents may be 
capable of infecting a particular host because they share 
structures which are extremely similar antigenically and 
immunogenically to those possessed by the host (Drach 
1973). Antibodies produced to the infectious agent may 
then be expected to cross-react with autoantigens. 
Finally# many bacterial agents and certain viruses (e.g. 
EBV) are capable of behaving as B cell mitogens. These 
are able to polyclonally activate B cells to produce a 
variety of antibody specificities including 
autoantibodies. From Dziarsky's work with the bacterial# 
polyclonal mitogen LPS (1982a# 1982b)# it would seem that
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either there is preferential stimulation of cells with 
autoantibody specificities/ or there are an extremely 
large number of such cells in the normal individual. 
Whatever the explanation of the appearance of 
autoantibodies in infectious disease/ they have been 
found to many different antigens in many diseases. 
Rheumatoid factors/ smooth muscle antibodies and ANA have 
been reported in many diseases (table 1.1).
-10-
Table 1.1 R F ,ANA and anti-smooth muscle (SMA) 
autoantibodies found in infectious diseases.
Antibody specificity
















Antibodies to cytoplasmic cytoskeletons have 
been frequently found in human sera/ and have been the 
subject of a recent review (Kurki and Virtanen 1984), The 
cytoskeleton of vertebrate cells consists of detergent 
and salt insoluble, cytoplasmic and nuclear fibrillar 
structures. The cytoplasmic cytoskeleton contains three 
major elements distinguishable by size; the microtubules 
(20-11 nm)/ intermediate filaments (7-11 nm) and the 
microfilaments (5-6 nm). Identification of cytoplasmic 
cytoskeletal structures can be achieved by their typical 
morphology or better still by the effect of certain drugs 
which specifically alter their cytoplasmic distribution. 
Cytochalasin B specifically disrupts microfilaments. 
Colchicine has no effect on microfilaments/ but disrupts 
microtubules and causes intermediate filaments of the 
vimentin type to collapse into a perinuclear bundle. 
Vinblastine again has no effect on microfilaments/ causes 
intermediate filaments to collapse into a perinuclear 
bundle and also disrupts microtubules leaving 
characteristic tubulin paracrystals in the cytoplasm 
(Norberg e_t a_l. 1979/ Pollard 1981/ Nagayama and Dales 
1970/ Goldman and Knipe 1973/ Kuznetsov et^  aJL. 1981/ 
Luduena ejt al^ . 1981).
Serum antibodies to cytoskeletal structures 
have been reported to be elevated in a many autoimmune 
and infectious diseases (Tables 1.2/ 1.3/ 1.4 after Kurki 
and Virtanen 1984/ Pedersen et al. 1982).
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Table 1.2 Microfilament antibodies in human sera.








Table 1.3 Microtubule antibodies in human sera.













Table 1.4 Intermediate filament antibodies in human sera.












The specificity of microfilament antibodies is 
mainly anti-actin (Lindman et al. 1976/ Kurki et a l . 
1980). It has been shown by affinity chromatography that 
sera from normal blood donors may contain trace amounts 
of antibodies to actin and tubulin (Guilbert et a l .
1982). An increased incidence of antibodies against 
myosin has been demonstrated in sera from patients with 
polymyositis . (Wada et a l . 1983). Patients with CAH may 
also have circulating antibodies to erythrocyte spectrin 
(Gorbars ejt a_l. 1981).
Microtubule antibodies are rare in the normal 
population. Increased tubulin binding activity has been 
observed in patients with alcoholic liver disease (Kurki 
et a l . 1983) and in patients with infectious 
mononucleosis or autoimmune disease of the endocrine 
organs as compared to healthy controls or systemic 
autoimmune patients. Most patients with CREST syndrome 
have antibodies to kinetochores (Moroi et a l . 1980).
Intermediate filament antibodies have been 
frequently reported in human sera. Antibodies 
(predominantly of the IgM class) are found to be elevated 
during acute viral infections such as hepatitis/ chicken 
pox/ measles/ mumps and infectious mononucleosis. Titres 
fall during convalescence (Toh et: a_l. 1979). 
Mortazavi-Milani et al. (1984a)/ reported the appearance 
of elevated titres (>1:80 by immunofuorescence against 
fibroblasts) of anti-intermediate filament antibodies in 
82% of sera from acutely infected malaria patients.
Similar levels were found in rabbits infected with 
Trypanosoma brucei (Mortazavi-Milani et^  al. 1984b). Serum 
antibodies to intermediate filaments and other 
cytoskeletal components have been found in infectious 
mononucleosis/ and such antibodies can be elicited 
in vitro by infection of normal PBL with EBV (Whitehouse 
et al.1974, Mortazavi-Milani et^  aJL. 1982). 74 out of 113 
sera from patients with infectious hepatitis, chickenpox, 
measles and mumps reacted with intermediate filaments of 
cultured fibroblasts (Toh e_t al^ . 1979). The class of 
immunoglobulin was predominantly IgM, and elevated titres 
were seen in the acute phase of infection. Titres fell in 
convalescence.
In all these cases, autoantibodies are formed 
during an infection and recovery is accompanied by loss 
of autoantibody production. This contrasts to the 
situation found in autoimmune disease where autoantibody 
production is a chronic condition.
3. Autoimmune disease.
This describes severe derangements of the 
immune network that are essentially non-reversible from 
within the immune system and lead to pathological 
conditions. It would simplify matters if the term 
autoimmune disease was applied only to those cases where 
it can be shown that the autoimmune process contributes 
directly to the pathogenesis of the disease. In practice
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however/ it is usually the case that all chronic diseases 
clearly associated with autoantibody formation are 
regarded as autoimmune/ unless it can be shown that the 
immunological phenomena are purely secondary. This 
reflects our state of ignorance of the role of 
autoimmunity in disorders involving immunological 
abnormalities/ and means that the distinction between 
autoimmunity and autoimmune disease is necessarily 
blurred.
4. Classification of autoimmune diseases.
In the absence of a known underlying mechanism 
for autoimmune disease/ these diseases are usually 
classified as organ-specific or systemic/ or at some 
point on the spectrum between the two. In organ-specific 
autoimmune disease/ the antibodies are usually specific 
for one or more antigens of a particular organ or tissue 
and the lesions are confined to these regions. 
Furthermore/ the lesions can be reproduced experimentally 
in animals/ to a certain degree/ by injecting the antigen 
in Freund's complete adjuvant. One example of an organ 
specific autoimmune disease is Hashimoto's thyroiditis.
In this case there is a specific lesion in the thyroid 
involving infiltration by mononuclear cells/ destruction 
of follicular cells and germinal centre formation/ 
accompanied by the production of circulating antibodies 
specific for thyroid constituents. Other examples of
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organ-specific autoimmune diseases include 
encephalomyelitis/ orchitis and pernicious anaemia.
At the other end of the spectrum are the 
non-organ specific or systemic diseases. These are 
characterised by the presence of antibodies to various 
tissue or organ antigens/ and the lesions are widespread. 
The classical example of this type of disease is systemic 
lupus erythematosus (SLE). Pathological changes are 
widespread and mainly characterised by lesions to 
connective tissue affecting the skin/ kidney glomeruli/ 
joints/ serous membranes and blood vessels. An extremely 
varied assortment of autoantibody specificities is seen/ 
including antibodies to DNA and other nuclear components 
found in all cells of the body. Other examples include 
scleroderma/ mixed connective tissue disease (MCTD) and 
rheumatoid arthritis (RA).
Many autoimmune diseases fall between these 
extremes. They usually involve antibodies capable of 
reacting with various tissues/ even though the lesions 
may be restricted. An example is myasthenia gravis (MG)/ 
where the primary lesion is a loss of functional 
acetylcholine receptors (AChR) on skeletal muscle. 
Antibodies to AChR are found in the serum and there is 
much evidence to suggest that they are responsible for 
the muscular weakness observed in the disease. However/ 
some myasthenics have antibodies to other antigens e.g. 
ANA and anti-striated muscle antibodies. Sjogren's 
syndrome/ primary biliary cirrhosis and some forms of
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haemolytic anaemia are also examples of 'intermediate* 
autoimmune diseases.
That this classification may be of some 
aetiological significance is suggested by the finding of 
overlap of autoimmune disorders. There is a tendency for 
more than one autoimmune disorder to occur in the same 
individual/ and when this happens the association is 
often between diseases within the same region of the 
autoimmune spectrum. Thus patients with autoimmune 
thyroiditis have a much higher incidence of pernicious 
anaemia than would be expected. Serologically there is 
even greater overlap. Thyroid antibodies for example/ are 
found in 50% of pernicious anaemia patients (Roitt 1980). 
At the non-organ specific end of the spectrum SLE is 
clinically associated with RA/ haemolytic anaemia/ 
dermatomyositis and Sjogren's Syndrome. ANA and RF are 
common features in all these disorders (Roitt 1980).
There is also an increased tendency to develop 
cancer in autoimmune disease. In patients with organ 
specific disease/ cancer of the target organ is more 
likely/ whereas non-organ specific disease patients are 
more susceptible to generalised lymphoreticular cancer.
5. Theories of tolerance to self antigens, and mechanisms 
of breakdown in autoimmune disease.
Because of anatomical barriers/ certain body 
constituents do not normally come in contact with the
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lymphoreticular system. Consequently immunological 
tolerance is not established. Any trauma which results in 
the release of these sequestered antigens would then 
provide an opportunity for autoantibody formation. In the 
case of sperm and lens/ this seems to be the case/ as 
experimental release of these components directly into 
the circulation can provoke autoantibody formation. 
However/ the great majority of autoantigens involved in 
autoimmune diseases are not sequestered/ and the 
injection of unmodified extracts of tissues does not 
elicit autoantibody formation. Thus one has to consider 
what the normal mechanisms of control of the autoimmune 
response are/ and how these may be by-passed in 
autoimmune disease.
In 1975 Nossal extended and subtly altered 
Burnet's deletion theory. He proposed that at some stage 
in their maturation from stem cells to antibody producing 
cells/ B lymphocytes go through a phase during which 
contact with antigen induces only tolerance and not 
immunity. This differs from Burnet's theory in that the 
stage of differentiation of the lymphocyte is important 
rather than the whole animal. Indeed it could be shown 
that primary B cells which start to express surface IgM 
are highly susceptible to induction of tolerance/ and 
that tolerance is very rapidly induced in these cells 
(Nossal and Pike 1975/ Metcalf and Klinman 1976/ Nossal 
et a l . 1979). The mechanisms of this tolerance induction 
are unknown/ but it may be related to the observation
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that immature B-cells are unable to regenerate receptors 
once removed by antigenic modulation (Bruynes et^  a l . 1976/ 
Raff et: al.1975). Since B-cells have a short life span/ 
and as there is a continuous generation of new B-cells/ 
functional inactivation has to be a continuous process 
whenever new lymphocytes mature that possess receptors 
for self determinants. Thus there may be circumstances 
under which some B-cells with anti-self activity escape. 
The concentration of autoantigen may be too low/ or the 
affinity of the antibody may be too low for the antigen. 
Tolerance in immature B-cells is more easily induced with 
multivalent antigens (Metcalf and Klinman 1976/ Elson
1977) and in clones with high affinity receptors rather 
than low affinity receptors (Nossal e^ t aJL. 1979).
Although elimination of particular clones of lymphocytes 
may thus play a role/ there are probably other more 
important processes that produce self-tolerance.
It has been demonstrated that antibody can 
contribute to an unresponsive state by competing with 
lymphocyte receptors for available antigens (Dresser and 
Gowland 1964). Passively administered antibody will 
specifically depress the immune response and high 
affinity antibody is more effective in bringing about 
antibody mediated suppression than low affinity antibody 
(Siskind et: al. 1968). However/ there is no evidence that 
serum antibodies play a major part in most examples of 
immune tolerance.
Antigens must be 'seen' by the T cell in the
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context of association with an MHC component on the 
surface of an antigen-presenting cell (APC). It has been 
speculated that the autoantigens do not have the 
opportunity or the mechanism to associate with the APC 
MHC in an effective manner. Thus autoimmunity would arise 
if the autoantigens could be adequately processed by the 
APC (Mitchison 1982). A situation might be envisaged in 
which unusual recruitment of APC to a given organ might 
increase the concentration of processed autoantigen to 
levels capable of triggering autoreactive lymphocytes. 
Alternatively autoimmunity might arise from derepression 
of genes coding for Ia-like (HLA-DR) antigens/ so 
allowing their expression in the plasma membrane and
thereby making the normal surface components potentially
antigenic. Indeed Pujol-Borrell and colleagues (1983) 
have demonstrated that normal human thyroid follicular 
cells could be induced to express HLA-DR antigens by the
lectins PHA and Con A.
Anti-idiotype antibodies can depress the 
production of antibodies bearing that idiotype and are 
therefore capable of maintaining a state of tolerance. 
Anti-idiotype antibodies can functionally delete clones 
of idiotype bearing B cells (Strayer £t a_l. 1974, Kohler 
et a l . 1974), and can also specifically inhibit secretion 
of that idiotype by mature antibody-secreting plasma cells 
(Schrater ejt al^ . 1979, Goidl et al^ . 1979, 1980). However, 
the action of anti-idiotype antibody, at least in adult 
animals, does not appear to result in irreversible clonal
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deletion (Fernandez and Moller 1980),
The activity of lymphocyte effector cells of 
both T and B lineages is regulated by at least two types 
of lymphocytes: T helper cell and T suppressor cells. 
Containment of autoreactivity might be achieved either by
(i) the activation of suppressor T cells or (ii) the 
inactivation of helper T cells. There is evidence for the 
existence of both mechanisms. Helper T cell tolerance can 
be induced by low doses of antigen (Weigle 1971)# but can 
be terminated fairly easily by cross-reacting antigens 
and polyclonal activators (Elson et a_l. 1979). It has 
therefore been suggested that suppressor T cells (induced 
by antigen or anti-idiotypic interactions) also operate 
to ensure a lack of reactivity to self-antigens (Siskind 
1984).
Two major mechanisms are thought to be 
responsible for the breakdown of self-tolerance in 
autoimmune diseases: T cell bypass and disordered 
immunological regulation. As discussed above/ tolerance 
appears to be maintained at the T cell level rather than 
the B cell. Since B cells usually need the help of T 
cells to differentiate into antibody-secreting cells# the 
overall effect is tolerance. Thus any mechanism which can 
circumvent the T cell requirement# or cause T helper cell 
activation may lead to the activation of non-tolerant B 
cells. Such mechanisms include: drugs that bind to body 
constituents# partially degraded autoantigens# bacterial# 
viral and parasitic infections. Many drugs are known to
-23-
cause autoimmune thrombocytopaenia/ haemolytic anaemia/ 
leukopaenia and immune complex syndromes. Some autoimmune 
manifestations following drug administration are 
remarkably specific. In patients treated with 
alpha-methyldopa/ haemolytic anaemias are not uncommon 
(Worlledge ejt a_l. 1966). Often the autoantibody is 
directed against the e antigen of the Rh series. The 
production of ANA is frequent in patients treated with 
procaineamide (Dubois 1969) and hydralazine 
(Alarcon-Segovia et a l . 1967). It seems likely that these 
results follow from the coupling of the drug or a 
metabolite to an autoantigen. If host T cells can react 
with the antigenic determinants of the drug/ 
autoantibodies could be formed through a helper effect. 
This has been demonstrated experimentally. Rabbit 
thyroglobulin coupled with arsanilic acid elicits the 
formation of autoantibodies in rabbits/ even in the 
absence of adjuvants (Weigle 1965). Coupling of 
dinitrophenol (DNP) to myeloma proteins has been used to 
elicit the formation of anti-idiotypic antibodies in 
syngeneic mice sensitised to DNP (Iversen 1970). A 
lupus-like syndrome has been described in patients 
treated with nitrofurantoin. These patients show evidence 
of cell-mediated reactions to nitrofurantoin/ but no 
antibody binding the drug has been observed (Pearsall 
et a l . 1974)/ compatible with the drug functioning as a 
helper determinant.
Partially degraded self-components may expose
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antigenic determinants to which the immune system may not 
be tolerant/ and thus may elicit an immune response. This 
has been investigated using rabbit thyroglobulin digested 
by papain as an immunogen in rabbits (Anderson and Rose 
1971). Intravenous injection of the cleavage products 
without adjuvant elicited the formation of autoantibodies 
against thyroglobulin, and mononuclear infiltrates were 
apparent in the rabbit thyroid gland. Partially degraded 
collagen is likewise immunogenic in experimental animals 
(Steffen 1969). The spleens of normal, non-immunised mice 
contain many cells that make plaques in target layers 
consisting of their own erythrocytes pre-treated with 
proteolytic enzymes (Cunningham 1976).
Many microorganisms possess or release 
substances (lipopolysaccharide, tuberculin, B.Pertussis 
components) that act as polyclonal B cell and T cell 
mitogens. That such substances induce autoimmune disease 
is demonstrated by the fact that Freund's adjuvant is 
widely used to induce experimental autoimmune diseases.
As has been mentioned, LPS can stimulate murine 
lymphocytes to secrete autoantibodies iji vitro and 
in vivo (Dziarsky 1982a, 1982b). Hammarstrom et a l .
(1976) found that bovine spleen cells cultured with 
polyclonal activators also produce antibodies to 
autologous RBC. Thus bacterial infections could produce 
polyclonal lymphocyte activation and autoimmunity. 
Moreover, bacteria might provide helper determinants, or 
might bear antigens eliciting antibodies capable of
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cross-reacting with autoantigens.
Viral infections might be expected to elicit 
autoantibodies in two ways. Viral antigens and 
autoantigens may become associated to form immunogenic 
units. Viral antigens stimulating host T cells could then 
function as helper determinants. Host antigens are 
incorporated into the envelopes of some viruses/ and 
virus antigens frequently appear on the surface of 
infected host cells (Burns and Allison 1975). Virus coded 
polymerases can be immunogenic in animals/ and these 
might function as helper determinants when bound to host 
nucleic acids.
It should be emphasised that such bypass 
mechanisms for the induction of autoimmunity do not by 
themselves ensure the continuation of the response. It 
seems likely that some defect in the regulatory control 
of self-reactive clones is required before an autoimmune 
response can become established. Several reports have 
documented defects in the T suppressor circuits in 
various autoimmune strains of mice (Cantor ejt aJ. 1978). 
There is evidence that the generation of non-specific 
suppressor T cells by polyclonal activators in patients 
with SLE is defective (Horowitz el: al. 1977, Fauci et^  a l .
1978). A significant proportion of clinically unaffected 
close relatives of these patients also demonstrate 
abnormally low levels of suppressor T cells (Miller and 
Schwartz 1979). This indicates that this deficit in SLE 
patients is not a result of the disease or its treatment.
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and that additional factors must be involved in the 
causation of the disease.
A mechanism by which T suppressor cells might 
be deleted has been suggested by Alarcon-Segovia (1978,
1979). They demonstated that anti-RNP antibodies could 
penetrate live mononuclear cells having receptors for the 
Fc portion of IgG. T suppressor cells have such 
receptors, and this suppressor function was found to be 
abrogated by anti-RNP iji vitro. Suppressor T cell loss or 
dysfunction caused by penetration of ANA into 
T suppressor cells may thus lead to a self-perpetuating 
autoimmune state. However, it is difficult to account for 
the antigenic specificity of different autoimmune 
disorders on the basis of a generalised depression in 
non-specific T suppressors without invoking defects in 
antigen-specific suppressors.
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1. Introduction.
SLE and MG are two autoimmune disorders which 
provide a number of interesting contrasts. In the 
spectrum of autoimmune diseases they are well separated, 
with MG near the organ specific end and SLE very clearly 
at the non-organ specific extreme. Only rarely are both 
diseases found in the same individual. In MG, although a 
number of autoantibody specifities may occur, anti- AChR 
antibodies predominate, whereas in SLE numerous 
autoantibody specifities abound. The pathological 
symptoms of MG are fairly clearly seen to be the result 
of anti-AChR antibodies interfering with the normal 
physiological functioning of its target antigen. In SLE, 
many of the symptoms are attributable to antibody-antigen 
complex deposition and consequential,local inflammatory 
tissue destruction. Autoantibodies are thus able to exert 
pathological effects without necessarily influencing the 
normal functioning of the antigen, and may produce 
lesions well away from the normal site of the target 
antigen. Some of the intracellular autoantigens in SLE 
are probably not even accessible to autoantibodies while 
functioning in viable cells. The function of certain 
nuclear and cytoplasmic antigens recognised by SLE sera 
(such as the ribonucleoproteins) are unknown, but their 
ubiquity would suggest they are probably of fundamental 
importance. The study of these antibody/antigen systems 
may provide insights into normal cell function.
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2. Clinical manifestations of SLE.
SLE is characterised by inflammatory and 
destructive processes in a variety of tissues and organs 
including the skin/ joints/ kidney/ heart/ lungs/ 
arteries and arterioles. The pathological changes occur 
primarily as a result of complement-fixing immune 
complexes (Brentjens £t a_l. 1977/ Koffler ejt a_l. 1982). 
The condition is more prevalent in women than men and has 
a peak incidence in the 25-29 year age group.
Clinical manifestations of the disease are 
extremely diverse. Lesions include erythemas of the skin 
(such as the classical facial butterfly rash)/ maculae/ 
bullous and ulcerous lesions/ arthritis/ arthralgia/ 
myositis/ myalgia/ damage to arteries/ lachrimeal and 
salivary glands/ pericarditis/ interstitial pneumonia/ 
glomerulonephritis/ haemolytic anaemia/ thrombocytopaenia 
and leukopaenia.
The clinical diagnosis of SLE is usually based 
on the American Rheumatism Association's preliminary and 
revised criteria for the classification of SLE (Cohen 
et a l . 1971/ Tan ejt al. 1982). In its revised form this 
consists of 11 clinical and serological criteria 
including a positive anti-nuclear antibody (ANA) 
fluorescent test/ and the presence of anti-DNA or anti-Sm 
antibodies (see table 2.1). Four of the 11 criteria must 
be met for the diagnosis of SLE. The inclusion of the ANA
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test in the revised criteria was found to increase the 
sensitivity of the diagnosis (Levin et al. 1984).
-31-








7. Renal disorder: persistent proteinuria or cellular 
casts
8. Neurological disorder: seizures or psychosis
9. Haematological disorder: haemolytic anaemia or 
leukopaenia, lymphopaenia or thrombocytopaenia
10. Immunological disorder: positive LE/ anti-DNA, 
anti-Sm or false positive serologic test for syphylis
11. Antinuclear antibody
(After Levin et al. 1984, Tan et al. 1982).
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3. Aetiology of SLE.
The aetiology of SLE is uncertain and many 
factors are implicated/ such as UV light/ drugs and viral 
infection/ with the involvement of a genetic 
predisposition for the disease and sex hormone levels.
A viral role for the onset of SLE has long been 
suspected. Paramyxovirus-like structures have been found 
in the kidney/ skin and circulating lymphocytes of SLE 
patients/ and a variety of serum antibodies have been 
found to viruses such as parainfluenza/ rubella/ 
reovirus/ polio/ adenovirus/ cytomegalovirus/ Herpes 
simplex and Epstein-Barr virus (Hurd ej: al. 1972/ Pincus 
et al. 1978/ Pincus 1982). A viral aetiology is also 
suspected in NZB mice which develop an SLE-like disease.
A type C oncornovirus is specifically implicated/ as a 
viral glycoprotein of Mr 20k is present in high 
concentration in the blood and spleen/ and also deposited 
as an immune complex in the glomeruli (Yoshiki ejt a l .
1974). However/ the role of viruses in human SLE remains 
hypothetical/ and no virus has been shown conclusively to 
be responsible for the disease.
Among the drugs which have been demonstrated to 
induce autoantibodies and a clinical SLE-like syndrome 
are procainamide/ hydralazine/ chloropromazine/ 
isoniazid/ trimethadone and alpha-methyldopa. These 
substances are able to interact with DNA and 
nucleoproteins in vitro, and induce ANA in individuals
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receiving them. Unlike 'spontaneous1 SLE/ racial and 
sexual predispositions are not seen/ the symptoms are 
generally milder and remission is usually complete on 
cessation of the drug.
That approximately 9 women contract the disease 
for every 1 man strongly suggests that sex hormones may 
play a role in the disease. During pregnancy/ an 
exacerbation of the disease/ which extends to the post 
partum period/ is common. Talal ejt a_l. (1982) found that 
androgens relieve the symptoms in female NZB mice/ and 
that castration of male NZB mice induced aggravation of 
the disease.
The incidence of SLE is higher in negro women 
than Caucasians/ and familial studies indicate a slight 
association of susceptibility to SLE with HLA-D2/D3 types 
(Estes and Christian 1971/ Grigor ejt a^ L. 1978/ Fessell 
1974/ Inman 1978). First degree relatives have been 
reported to have a higher incidence of ANA (4.2%) than 
normals (0-1%) and also show a high incidence of 
Raynaud's phenomenon (Block et^  a_l. 1975). In many cases/ 
members of the patient's family show other autoimmune 
manifestations such as hypergammaglobulinaemia/ and a 
high frequency of rheumatoid arthritis (RA). Concordance 
of disease in monozygotic twins is high; 57% for SLE/ 71% 
for ANA and 87% for hypergammaglobulinaemia (Block ejt a l . 
1975). Concordance is lower in dizygotic twins.
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4. Autoantibodies in SLE.
The most prominent abnormality in patients with 
SLE is their ability to produce antibodies to a 
spectacular range of self-antigens. Some examples of 
autoantibody specificities found are given in table 2.2.
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The antinuclear antibodies have been 
particularly implicated in the pathogenesis of SLE and 
related diseases (Reichlin 1981). The number of distinct 
nuclear antigens recognised by SLE sera is large. 
Antibodies to various nuclear antigens differ in their 
diagnostic specificity for SLE/ their relationship to 
disease activity and their postulated role in the 
disease.
4(i). Antibodies to DNA.
Anti-DNA antibodies occur frequently in active 
SLE with anti-dsDNA antibodies being nearly exclusively 
found in the disease (Tan et al. 1966/ Koffler et^  a l . 
1971). They are closely related to disease pathogenesis 
through the process of immune complex formation. 
Exacerbation of the illness/ with high fever and 
proteinuria coincides with the appearance of DNA in the 
serum and the disappearance of antibodies. Hence 
monitoring levels of anti-DNA antibodies has value in 
predicting disease flare-up (Swaak et^  al^ . 1982). A 
considerable heterogeneity in anti-DNA responses is seen. 
There are many differences between sera in the 
quantitative and qualititive features of these 
antibodies/ in their ability to form immune complexes and 
cause inflammatory damage (Winfield et al^ . 1977/ Miniter 
et a l . 1979).
There are difficulties in studying antibodies
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to DNA, As an antigen, DNA displays many structural forms 
and sequence patterns that can serve as antigenic 
determinants (Wells et a l . 1980), Considerable attention 
has been devoted to the distinction between antibodies to 
dsDNA as opposed to antibodies to ssDNA. However, 
obtaining pure dsDNA is difficult and small breaks or 
gaps may allow the binding of anti-ssDNA antibodies. Even 
intact DNA may reveal regions of single-strandedness. 
Similarly, pure ssDNA may be difficult to obtain (Stoller 
and Papalian 1980). Regions of complementarity along two 
DNA molecules may generate duplex regions in ssDNA 
preparations. It should also be noted that components of 
sera may affect the conformation of DNA, so that even 
specifically defined DNA preparations may undergo changes 
during assay (Pisetsky 1983). With such heterogeneity, 
assessment of antibody response can be difficult.
4( ii). Antibodies to small nuclear and cytoplasmic 
ribonucleoproteins.
SLE serum antibodies are capable of binding a 
number of soluble nuclear and cytoplasmic
ribonucleoproteins. These are complexes of small RNAs and 
protein found in eukaryotic cells. The RNA components 
are distinct from the three commonly encountered RNAs 
i.e. mRNA, tRNA and rRNA (Lerner and Steitz, 1981, Zieve
1981). Four principle ribonucleoproteins are bound by 
sera from SLE, MCTD, RA, Scleroderma and Sjogrens
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Syndrome patients. These are Sm, nRNP, La and Ro. The 
presence of autoantibodies to these, together with their 
titre and specificity , is an important clinical feature 
for the diagnosis of these diseases.
The Sm antigen is a non-histone, nuclear, 
acidic protein. It is highly soluble in physiological 
salt solution and is insensitive to RNase, DNase and 
trypsin except on prolonged exposure. It is mostly, if 
not entirely found in the nucleus, and gives a speckled 
staining pattern by indirect immunofluorescence (Lerner 
et a l . 1981). There has been little consistency in the 
literature regarding the protein composition of the Sm 
antigen. Several laboratories have found that the 
polypeptides associated with this antigen are within a 
range of Mr 12k-14k (Agelli ^t a_l. 1980, Takano et^  a l . 
1980, 1981). However, the lower Mr polypeptides are 
reported as representing either minor (Lerner ejt a l .
1980), or major (Barque ejt aJ. 1981) components. 
MacGillivray et al^ . (1982) reported four components of Mr 
/~10k and one component of Mr^12k. Five similar 
polypeptides were found by Lerner and Steitz (1980), 
although the Mr estimates differed slightly. Billings and 
Hoch (1983) found the antigenic polypeptides to consist 
of a 26-27k doublet and one 13k polypeptide. Also present 
were non-antigenic components of 35k, 32k, Ilk and <10k. 
There is also discrepancy in the analysis of the RNA 
content of Sm. Lerner and colleagues (1979, 1980, 1981), 
and Mount and Steitz (1981) reported the Sm antigen to
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con tain six RNA subunits designated Ula/ Ulb/ U2, U4, U5, 
U6. MacGillivray e_t aJL. (1982) found 10 RNA species 
migrating in PAGE between 4S and 5S. Similar species were 
reported by Takano ejt a_l. (1980/ 1981) and White et: a l .
(1981).
Anti-Sm antibodies are found in approximately 
25-30% of SLE patients (Nakamura et al. 1978)/ and they 
occur almost exclusively in SLE. Their presence is taken 
as a diagnostic marker for the disease (Kurata and Tan 
1976/ Tan et al. 1982). Anti-Sm antibodies are primarily 
of the IgG class and are usually found with anti-nRNP 
antibodies. Where anti-Sm is found alone/ there may be a 
greater chance of the patient suffering nephritis 
(Sabaharval et al. 1983).
The nRNP antigen is a nuclear/ non-histone 
protein. Its antigenicity is destroyed by both RNase and 
trypsin (Takano ejt aJL. 1980/ Douvas ejt a_l. 1979). The 
complex precipitated by anti-nRNP sera contains two RNA 
species/ Ula and Ulb/ both of which are also found in the 
Sm antigen. Other workers have reported the presence of 
smaller RNA species (MacGillivray and Carroll 1982/
Takano eit al. 1980/ 1981). The Sm and nRNP antigens have 
independent antigenic determinants (Lerner £lt aJL. 1980)/ 
although both antigens can be found complexed to the same 
Ul RNA (Lerner ejt al. 1982). The number of polypeptides 
in nRNP has been reported to be between 5 and 9, and of 
Mr between 9k and 65k (Lerner and Steitz 1979/ Gibbons 
et al. 1982/ Takano et al. 1980/ White et al. 1981/
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Douvas and Tan 1981). Recently Billings and Hoch (1983) 
isolated Sm/nRNP from rabbit thymus by an affinity column 
of SLE IgG with both Sm and nRNP reactivities. The 
proteins isolated were run on reducing gels and analysed 
by immunoblot and Coomassie staining. The nRNP specific 
polypeptide was found to have a Mr of 73k. The 
conflicting data from the analyses of Sm and nRNP 
probably results from different methods of antigen 
detection/ different cell and tissue sources and 
different extraction and isolation procedures.
Antibodies to nRNP are found in SLE/ MCTD/ 
Scleroderma and Sjogren's Syndrome/ with the highest 
titres usually found in MCTD patients (Notman ejt a l .
1975). In SLE/ anti-nRNP antibodies are found in 23-50% 
of patients/ often with antibodies of other specificities 
(Kurata and Tan 1976/ Tan et al. 1976). By indirect 
immunofluorescence they give a speckled nuclear pattern 
(Provost 1979)/ and are of the IgG class. In SLE/ 
anti-nRNP antibodies are usually found in conjunction 
with anti-Sm/ whereas in MCTD anti-nRNP are found without 
anti-Sm. The presence of anti-nRNP as the sole precipitin 
is indicative of a subset of patients with low incidence 
of renal disease and CNS involvement (Notman ejt al^ . 1975/ 
Provost 1979/ Sharp 1982). When found in conjunction with 
other antibodies/ the presence of anti-nRNP may be 
related to a high incidence of nephritis (Reichlin 1981). 
Anti-nRNP antibody has been found in complexes deposited 
in glomerular lesions (Kuraka 1979).
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The La antigen is a soluble nuclear protein 
which is sensitive to trypsin but resistant to both DNase 
and RNase (Teppo «jt a_l. 1982). Although early reports 
suggested it was found in both nucleus and cytoplasm/ it 
is now believed that the location of it in the cytoplasm 
was an artefact arising during the biochemical 
fractionation (Hendrick ejt aJL. 1981/ Hardin et_ al. 1982). 
The Mr of the antigenic polypeptides have been variously 
estimated between 30k and 68k (Francoeur and Mathews 
1982/ Teppo et^  al. 1982). Antibodies to La are found in 
sera from patients with RA/ SLE and Sjorgren's syndrome 
(Provost 1979). Sera with anti-La antibodies frequently 
contain antibodies to Ro.
The Ro antigen is a soluble, cytoplasmic, acidic 
glycoprotein which is resistant to both RNase and 
trypsin. The Ro protein is complexed with between 2 and 5 
sRNAs/ depending on the mammalian species (Hendrick 
et a l . 1981/ Reddy et: al. 1983). These sRNAs vary in size 
from 800-110 nucleotides and are distinguishable from the 
U series which are components of Sm and nRNP (Lerner 
et a l . 1980/ Hendrick et aJL. 1981). By SDS-PAGE and 
immunoblotting/ Lieu ejt al^ . (1984) have found the 
antigenic polypeptide to have a Mr of 61k. Wolin and 
Steitz (1984) similarly reported a Mr of 60k.
Antibodies to Ro are found in about 30% of SLE 
patients and 25% of patients with Sjogren's Syndrome 
(Scopelitis et aJL• 1980). Whereas sera with anti-La 
antibodies frequently contain anti-Ro antibodies/ the
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converse is not true in that there are many sera with 
anti-Ro activity which are free of anti-La activity (Tan 
1982). When the antigens reactive with La and Ro 
antibodies are analysed/ it can be shown that distinct 
sets of small RNAs are precipitated by each antibody 
(Lerner et al. 1981)/ a situation different from the Sm 
and nRNP situation described above. Warsicek and Reichlin 
(1982) found that patients with SLE who possessed 
antibodies to Ro without antibodies to La have a high 
incidence of antibodies to DNA and serious renal disease. 
Maddison and Reichlin (1979) have demonstrated that 
Ro-anti-Ro immune complexes participate in the 
development of nephritis. Patients with both anti-Ro and 
anti-La antibodies have a lower incidence of antibodies 
to DNA and a very low incidence of nephritis/ and have 
milder disease symptoms (Warsicek and Reichlin 1982/ Tan
1982). In addition to the relationship of anti-Ro 
antibodies to SLE and Sjogrens syndrome/ many recent 
studies have shown that this antibody maybe related to 
neonatal lupus (Franco eJL a_l. 1981/ Kephart et a^ L. 1981/ 
Weston et a_l. 1982). Infants with neonatal lupus are 
characterised by the presence of anti-Ro antibodies and 
occassionally with anti-La but without other types of 
ANA. These antibodies are transferred across the placenta 
from the mothers who have all been shown to have the 
antibody. The infants do not produce these antibodies as 
after a period of several months the antibodies disappear 
from the circulation. A high incidence of congenital
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complete heart block has been observed in these infants 
and the correlation with anti-Ro is highly significant 
(Scott ejt al^ . 1983).
5. Clinical manifestations of M G .
MG is characterised by weakness and 
fatigability of skeletal muscles. This is frequently a 
progressive disease beginning with drooping of the 
eyelids, double vision, and impairment of speech and 
swallowing. The proximal muscles of the limbs and trunk 
are usually affected later/ and respiration may be 
adversely affected in severe cases. The neuromuscular 
junction was implicated as the region of the defect by 
the observation that anticholinesterases could improve 
the strength of MG patients (Walker 1934). The nature of 
the defect was not elucidated until the snake toxin 
alpha-bungarotoxin (alpha-BTX) became available as a 
specific probe for AChR (Lee 1972). Neuromuscular 
junctions of MG patients were found tg bind far less 
radiolabelled alpha-BTX than normals/ suggesting that the 
number of available AChR sites was far less (Fambrough 
et al^ . 1973). In addition/ the neuromuscular junctions of 
myasthenic patients were found to be considerably 
simplified morphologically (Engel and Santa 1971). The 
effect of these lesions is to immpair synaptic 
transmission/ resulting in failure of nerve impulses to 
trigger muscle action potentials and hence muscle
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contraction. An occurrence rate of 1 in 20,000 of the 
population has been suggested (Kurland 1957). The 
distribution of the disorder appears to be worldwide, and 
no ethnic groups seem to be particularly susceptible 
(Osserman 1958). The possibility that the CNS might be 
involved has been considered (Grashchenkov and Perelman 
1966), although firm evidence is lacking. The EEG can be 
abnormal in MG (Hokkanen and Toivakka 1969, Levfert and 
Pirskanen, 1977). Papazian (1976) reported that MG 
patients had a significant disturbance of rapid eye 
movement (REM) sleep, which in normal individuals is 
thought to depend on acetylcholine as the transmitter. 
Anti-AChR antibody has been found in the cerebrospinal 
fluid of MG patients (Levfert and Piskanen 1977) but 
appeared to gain access by passive leakage rather than 
being synthesised locally (Keesey et al. 1978). 
Micro-infusion of MG serum or its IgG fraction into the 
caudate nucleus of rabbit brain provoked an abnormal EEG 
discharge and abnormal behaviour (Fontana ejt a_l. 1978). 
The degree of these abnormalities appeared to correlate 
with the titre of the antibody and could be corrected by 
anticholinesterases.
An association of particular HLA antigens with 
MG was recognised by Pirskanen et: al. (1972) who found an 
increased frequency of HLA-B8 in young female patients. 
This has since been confirmed by several groups (Feltkamp 
et a l . 1974, Fritze e_t al^ . 1974, Van den Berg-Loonen 
et al. 1977).
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6. The nature of M G .
The autoimmune nature of MG was suspected 
because of its association with other autoimmune diseases 
(Simpson 1960)/ and the frequent structural abnormalities 
found in MG patients' thymus glands (Castleman 1966).
That the AChR was the object of an immune attack was 
first indicated by a fortuitous experiment of Patrick and 
Lindstrom (1973). In attempting to raise rabbit 
antibodies to purified AChR from the electric organs of 
eels/ they found that the immunised rabbits developed 
muscular weakness and other symptoms of MG/ including a 
decremental muscle response on repetitive stimulation.
The muscular weakness/ as in human MG/ was relieved by 
administration of anticholinesterases.
MG patients were then screened for the presence 
of serum anti-AChR antibodies. Approximately 90% of MG 
patients have detectable anti-AChR antibody/ and a RIA 
which measures antibody binding to human muscle AChR has 
now become a standard diagnostic procedure (Lindstrom 
et a l . 1976). Despite the common occurence of anti-AChR 
antibody/ the serum levels of such antibody corresponds 
poorly to the severity of the patients' symptoms.
7. The role of anti- AChR antibody in M G .
Do these circulating antibodies represent a
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secondary response to AChR damage caused by some other 
agent* or are they themselves the pathogenic agents? 
Immunoglobulin from MG patients,when repeatedly 
administered to mice, was found to induce characteristic 
features of MG. The component responsible was found to be 
IgG, and its effect was enhanced by complement (Toyka 
et^  a_l. 1977). Electron-microscope studies have identified 
IgG and complement at the postsynaptic membranes of MG 
patients' neuromuscular junctions (Engel et a l . 1979). 
Plasma exchange, which temporarily lowers serum 
concentrations of anti-AChR antibodies, results in a 
concomitant improvement in the strength of MG patients 
(Pinching £t a_l. 1976, Dau 1982).
Antibody induced reduction of available AChR 
could be produced by increasing the rate of degradation, 
decreasing the rate of synthesis, blocking the active 
site or by causing post synaptic damage in conjunction 
with complement fixation. There is evidence to support 
each of these possibilities. Probably the relative 
importance of each of these mechanisms depends upon the 
class, sub-class, fine specificity and affinity of the 
autoantibodies present.
Immunoglobulin from MG patients' sera has been 
found to increase the degradation of AChR of rat skeletal 
muscle in culture by 2-3 fold (Drachman e_t a_l. 1982).
This was apparently due to antigenic modulation of the 
receptor, as the increased degradation was not seen when 
Fab fragment of myasthenic IgG was used. Autoradiography
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and fluorescence microscopy have shown the addition of 
anti-AChR serum into muscle cultures to cause the AChR to 
aggregate into clusters (Lennon 1978/ Tarrab-Hazdai 
et a l . 1979), These are then believed to be endocytosed 
by coated pits in the muscle membrane and degraded in the 
interior of the cell (Pumplin and Drachman 1983). There 
is evidence that a similar increase in turnover of AChR 
occurs at intact neuromuscular junctions with the 
addition of MG IgG both iji vivo and iji vitro (Merlie 
et a l . 1979/ Reiness et al^ . 1978/ Stanley and Drachman
1978).
Whether direct blockade of AChR by serum 
antibody is an important pathological feature in MG is 
under debate. Between 7% and 90% of MG sera have been 
reported to block the ACh binding site (Almon et a l .
1974/ Drachman et a_l. 1982). Where blockade does occur it 
is likely to be due to the attachment of antibody near to 
the ligand binding site and effecting blockade by steric 
hindrance (Drachman 1981.
There is only a weak correlation between the 
clinical severity of MG and the amount of antibody 
capable of binding to AChR as measured by RIA. The 
functional ability of antibody to reduce the available 
AChR might give a better correlation. Drachman et. a l .
(1982) examined the ability of immunoglobulin from a 
large number of patients to induce degradation or 
blockade of AChR on cultured rat muscle. The ability to 
do this corresponded well with the clinical status of the
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patients. Some immunoglobulins were better at blocking 
and some at degrading/ indicating some functional 
heterogeneity in the autoantibody population. The 
potential of the antibody to produce disease may thus 
relate to epitopic specificities which either dispose to 
receptor blocking or degradation. Other properties are 
probably involved such as the ability to bind complement.
8. Aetiology of M G .
That marked differences exist between groups of 
patients suggests there are diverse origins of the 
disease even though the target of the autoimmune response 
is the AChR. Young females and older males are 
preferentially afflicted with the disease. Thymic 
abnormalities vary between groups; 25% have no 
abnormalities/ 65% have hyperplasia and 10% have thymic 
tumours. Familial occurence of the disease is 
occasionally seen and there is association with other 
autoimmune diseases in some but by no means all patients.
The frequent occurrence of thymic abnormalites 
in MG patients suggests some involvement in the disease. 
Surgical thymectomy produces clinical remission in 35% of 
patients and improvement is seen in up to 50% (Buckingham 
et al. 1976). The thymus contains not only lymphocytes 
but other cells including myoid cells. These strongly 
resemble skeletal muscle when cultured iji vitro (Kao and 
Drachman 1977/ Wekerle et al. 1975)/ and also possess
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surface AChR (Kao and Drachman 1977). This has been 
postulated as the source of antigen in MG. Newsome-Davis 
et a l . (1982) have demonstrated that there are B cells in 
the thymus of MG patients capable of producing IgG, some 
of which is directed against AChR. In vitro/ such 
lymphocytes can produce signficant amounts of anti-AChR 
antibody.
Several studies have examined the hypothesis 
that a virus may be the cause of MG. Antibodies to 
cytomegalovirus have been found in an increased 
proportion of MG patients (Tindall 1980)/ but neither 
this nor any other virus has been found in MG thymuses in 
systematic studies by electron microscopy (Drachman
1983).
A proportion of RA patients treated with 
penicillamine develop drug induced MG. This completely 
remisses with omission of the drug. Similarly the 
experimental administration of AChR initiates an MG-like 
syndrome in animals/ but repeated administration is 
necessary to perpetuate the disease. Thus if the trigger 
in MG is an altered form of AChR/ its continued presence 
would seem to be necessary. Alternatively the disease may 
result from a defect in immune regulation. There appears 
to be no overall deficiency of T suppressor cells in MG/ 
although the possibility of a deficiency of suppressor 
cells specific for anti-AChR antibody has been proposed 
(Shinomiya et^  aJ. 1981).
Although our understanding of SLE and MG has
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increased over recent years, clearly much remains to be 
learned. A precise understanding of the autoimmune 
response is necessary to discover how and why an 
autoimmune response is initiated and maintained in these 
disease states.
-51-
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A detailed knowledge of the structural and 
functional properties of both the autoantigens and 
autoantibodies in an autoimmune disorder is clearly 
necessary for understanding the cause and management of 
the disease process. Studies of autoantibodies are 
complicated by the fact that the sera of autoimmune 
patients often contain a complex mixture of 
autoantibodies. Thus in functional studies of 
autoantibody containing sera there is always the 
possibility that quantitatively minor but functionally 
significant autoantibodies may confound the 
interpretation of data (Hough et: aJ. 1982). Similarly it 
is very difficult to determine whether the observed 
multiple reactivities of autoimmune sera reflect a range 
of autoantibodies with different specificities, or 
autoantibodies with the same specificity reacting with a 
common determinant on different tissues. An homogeneous 
population of autoantibodies would theoretically allow 
both the types of problem to be resolved. Such 
populations of antibodies occassionally arise 
spontaneously. Monoclonal cold agglutinins (Dellagi et: 
a l . 1981), rheumatoid factors (Grey ejt a_l. 1968), and 
anti-nerve antibodies (Latov £t^ a_l. 1980) are such 
examples. Unfortunately they occur too infrequently to be 
of general use.
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2. Monoclonal antibodies (MCA).
Antibody-secreting lymphoid cells have a very 
short life when cultured iji vitro. Certain myeloma cell 
lines have been adapted to permanent growth in culture/ 
but the antibodies they produce are fixed and not of 
predefined specificity. When both types of cell are 
fused/ hybrids can be derived which retain the highly 
desirable properties of immortality and secretion of 
antibody with a desired specificity. As the hybrid cells 
can be cloned/ individual antibodies of exquisite 
specificity can be obtained indefinitely. The production 
of MCA in this fashion was first described by Kohler and 
Milstein (1975)/ and has made numerous complex biological 
systems amenable to precision analysis. In the area of 
autoimmunity this technology makes possible the study at 
the molecular level of both the autoantigens and the 
autoantibodies themselves. MCA lend themselves readily to 
the development of anti-idiotype antibodies. These are 
useful for detailed studies of the specificities and 
genetic origins of autoantibodies. In addition they may 
be used to manipulate the immune system and are thus 
potentially useful therapeutic agents.
3. MCA derived from immunised rodents.
A precise characterisation of the antigens 
involved in an autoimmune disease may be very important
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to the understanding of its aetiology and pathogenesis. 
One approach to utilising MCA technology in the study of 
autoimmunity has been to isolate the relevant antigen/ 
immunise rats or mice with it and raise a number of MCA.
A large number of such MCA are useful as probes for the 
antigen and allow fine definition of its antigenic 
structure. These MCA can also be used as 'model1 
autoantibodies to determine the pathological significance 
of various specificities. This type of approach has been 
taken with the study of anti-islet antibodies related to 
diabetes (Eisenbarth e^ t al^ . 1983) and the study of the 
thyrotropin receptor involved in Graves disease (Kohn 
et^  al^ . 1983). Probably the best example of this approach 
has been with the study of the AChR and its involvement 
in MG. These studies will be considered in detail as an 
example of this general approach.
3(i). Studies of autoantigens.
The AChR has been the subject of intensive 
study with MCA by a several groups of researchers. 
Lindstrom's group alone have generated a library of over 
140 MCA to intact AChR and AChR subunits purified from 
the electric organs of Torpedo californica (Tzartos and 
Lindstrom 1980/ Lindstrom 1983) and Electrophorus 
electricus (Tzartos ejt al^ . 1981), and to intact receptors 
purified from the muscles of cattle and humans (Tzartos 
and Lindstrom 1981).
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While these MCA were produced exclusively in 
rats, other groups have utilised both rats and mice 
(Dwyer £t a_l. 1981/ Fuchs e_t aJ. 1981/ Gomez ejt al^ . 1981/ 
James £t al^ 1980/ Lennon and Lambert 1981). About half 
the MCA raised against intact receptor react with 
denatured subunits prepared by dissociation in SDS 
(Gullick and Lindstrom 1982). When the subunit 
specificities of the MCA were examined/ many were found 
specific for only one subunit/ some weakly cross-reactive 
with one or more subunits/ and a few strongly reactive 
with more than one subunit (Tzartos and Lindstrom 1980/ 
Gullick and Lindstrom 1982). This cross-reaction probably 
reflects the extensive amino acid sequence homology 
between subunits (Raftery eJL a_l. 1980/ Conti-Tronconi et^  
a l . 1982). MCA against Torpedo AChR often cross-react 
with receptors from other species and have been used to 
localise homologous subunits in receptors from other 
species (Einarson et: aJL. 1982/ Gullick and Lindstrom 
1982/ Lindstrom et^  al^ . 1980). A large number of MCA react 
with a small portion of the alpha subunit which Lindstrom 
has called the Main Immunogenic Region (MIR). This is 
highly conserved between species/ is probably on the 
extracellular surface of alpha subunits and is distinct 
from the acetylcholine binding sites (Gullick e£ a l .
1981). It is probably identical to the immunodominant/ 
non-acetylcholine binding site found by Lennon and 
Lambert (1981).
Rodent MCA have been used to determine
-56-
anti-receptor specificities present in MG patients' sera 
(Tzartos ejt aJL. 1981). Six MCA of defined specificities 
were used to competitively inhibit the binding of serum 
anti-receptor antibodies to human muscle receptor. Two 
MCA to the MIR were used/ one MCA to another site on the 
alpha subunit/ one MCA to a site on the beta subunit/ and 
two MCA to the gamma subunit. A large fraction of MG 
serum antibodies were found to be inhibited by MCA to the 
MIR/ but very few by the MCA to the other alpha subunit 
site. MCA to determinants on both beta and gamma 
inhibited substantial amounts of serum antibodies. This 
strongly suggests that in MG/ antibodies are made to many 
parts of the receptor molecule/ and furthermore 
implicates the human muscle AChR as the immunogen rather 
than a cross-reacting antigen with limited structural 
similarity. The results also confirm that despite a 
predominant immune response to the MIR/ the autoimmune 
response is polyclonal/ involving anti-receptor antibodies 
of many specificities. This suggests that it might be 
difficult to achieve effective immune suppression with 
anti-idiotype antibodies to MCA.
3(ii)Use of MCA as model autoantibodies.
Monoclonal antibodies raised from immunised 
rodents have been used to examine some of the features 
which make auotantibodies pathological. Once again this 
will be discussed with reference to the AChR.
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Theoretically/ one would expect antibodies to 
the acetylcholine binding site to be of greatest 
pathological significance/ because of inhibition of 
receptor function. Serum antibodies (Barkas ejt a_l. 1982) 
and MCA (Gomez et al^ . 1979) have been recognised that 
bind sufficiently near the acetylcholine binding sites to 
inhibit toxin binding. Some MCA have been found that bind 
directly on the acetylcholine site (James et: aJL. 1980/ 
Mochly-Rosen and Fuchs 1981). These compete with agonists 
and antagonists for binding and inhibit receptor 
function. However/ there is little evidence that such 
antibodies play an important pathological role in most MG 
patients. Such antibodies represent a very small fraction 
of antibody specificities (Lindstrom et aJ. 1976) and 
their concentration correlates poorly if at all with 
severity of disease (Drachman cst aJL. 1982/ Compston ejt 
al. 1981). Electron microscopy studies reveal that in MG/ 
receptors are lost rather than blocked by antibodies 
(Engel ejt al. 1979).
In contrast to MCA to the acetylcholine binding 
site/ MCA to the MIR and most other sites so far studied 
do not inhibit receptor function (Lindstrom et^  aJL. 1983). 
However/ a single MCA can passively transfer EAMG (Gomez 
et al. 1981/ Kamo et a_l. 1982/ Tzartos and Lindstrom 
1980/ Lennon and Lambert 1981). As with passive transfer 
by serum/ passive transfer by MCA occurs by an acute 
process requiring complement (Lennon and Lambert 1981). 
Antibodies to the MIR seem to have a particular
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pathological significance. Of 4 MCA tested that bound to 
the MIR, all transferred EAMG (Tzartos and Lindstrom 
1980/ Lindstrom 1983). None of 4 MCA reactive with other 
sites transferred EAMG even though one MCA was 
demonstrated to have bound the beta subunit iji vivo 
(Lindstrom 1983). The relative importance of antigenic 
modulation and complement fixation in the ability to 
passively transfer EAMG is being studied using MCA with 
different specificities/ and with MCA of similar 
specificities but of different classes and subclasses 
(Lindstrom 1983).
4. Monoclonal autoantibodies from mice with autoimmune 
disease.
Unlike active immunisation/ where it may be 
assumed that elicited antibodies have been produced 
against the administered immunogen/ the substances which 
give rise to a spontaneous autoimmune disease are not 
known. It has not yet been shown that the same antigenic 
determinants are recognised in spontaneous disease as 
those recognised by an animal immunised artificially with 
the antigen. As Eilat (1982) has pointed out , this is an 
important distinction/ as it may turn out that whereas 
MCA raised by immunisation can be useful in studying some 
pathological consequences of autoantibody formation/ they 
may have no relevance to mechanisms leading to the 
development of spontaneous autoimmune disease. This is
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one reason why many workers have focussed their attention 
on raising MCA from mice which develop spontaneous 
autoimmune disease/ and human autoimmune patients 
themselves. SLE is well represented by mouse models and 
many hybridomas have been derived from such animals 
without prior immunisation.
4(i). Studies of autoantibody specificities.
Pages and Bussard (1978) were the first to 
report the successful establishment of permanent murine 
hybridomas which secreted monoclonal autoantibodies. 
Peritoneal cells from an unimmunised NZB mouse (a strain 
which develops SLE) were fused with mouse myeloma cells 
and hybrids were isolated which secreted MCA to 
erythrocytes. Several IgM secreting clones were isolated 
which produced MCA which were haemolytic for bromelin 
treated mouse red blood cells.
Most monoclonal lupus antibodies studied have 
been directed against nucleic acid antigens. Eilat ej: a l . 
(1980) obtained a hybridoma from an NZB/W Fl mouse which 
secreted a MCA to RNA. It was specific for ssRNA rather 
than dsRNA. It also reacted with random polymers 
poly(G,C) and poly(G/C/U)/ and apparently recognises an 
antigenic determinant containing (G)/(C) and (U).
Further studies on epitope specificity of 
anti-DNA antibodies were undertaken by Lee et: a_l. (1981). 
They examined 6 MCA/ derived from NZB/W Fl mice/ which
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bound ssDNA. By experiments with synthetic homo and 
heteropolymers of purines and pyrimidines they found the 
binding of all 6 MCA to be influenced by the base 
sequence of the antigens. Other workers have studied MCA 
to DNA that were derived from lupus mice/ including 
MRL-lpr/lpr (Andrzejewski et^  al^ 1980/ 1981)/ NZB/W Fl 
(Hahn et^  al^ . 1980/ Marion et^  a_l. 1982) and BXSB (Hahn e_t 
al 1980). In most cases the MCA reacted preferentially 
with ssDNA rather than dsDNA. However Tron e_t al^ . (1982) 
have described 10 MCA from NZB/W Fl mice that react 
preferentially with dsDNA.
Andrzejewski et a l . (1981)/ using MCA from 
MRL-lpr/lpr mice have demonstrated that a single 
autoantibody can bind to multiple nucleic acid acid 
antigens of widely different base composition. They 
suggest that these type of antibodies recognise the sugar 
phosphate backbone common to all nucleic acids. Further 
analyses have shown that some MCA to DNA can also bind 
phospholipids/ including cardiolipin. Absorbtion of such 
autoantibodies with cardiolipin micelles inhibits their 
ability to produce the fluorescent ANA reaction. These 
results support the notion that some lupus autoantibodies 
can manifest a variety of serological abnormalities. The 
antibodies that binds to DNA and cardiolipin can explain 
the origin of the biological false positive test for 
syphilis in SLE. Also since anti-DNA autoantibodies can 
bind to other molecules/ it is evident that DNA is not 
necessarily the immunogen or even the preferred target
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antigen in SLE,
Lerner e^ t al. (1981) produced MCA from 
MRL-lpr/lpr mice specific for either Sm, DNA or nRNP. In 
immunoprecipitation studies,the mouse anti-Sm gave an 
identical pattern of precipitation to a human anti-Sm 
serum. The monoclonal anti-Sm used in a competitive RIA 
has shown that at least one antigenic site/ recognised by 
the monoclonal antibody/ is distinct from nRNP (Lerner et^  
al. 1982).
4(ii). Anti-idiotypic analyses of monoclonal 
autoantibodies.
Several groups have investigated the idiotypes 
of monoclonal anti-DNA antibodies. Rauch et aJJ. (1982) 
prepared a polyclonal rabbit anti-idiotypic antiserum 
against a monoclonal anti-DNA antibody from an 
MRL-lpr/lpr mouse. This antiserum reacted with 8/12 other 
MRL derived anti-DNA MCA/ and detected the presence of 
the idiotype in 40/40 MRL sera. Tron ejt a_l. (1982) 
prepared a monoclonal anti-idiotype antibody by 
immunising a mouse with a monoclonal anti-DNA derived 
from an NZB/W Fl mouse. This recognised the immunising 
idiotype in all 24 NZB/W Fl sera tested. Marion elt a l . 
(1982) analysed a rabbit antiserum directed to the 
idiotype of a monoclonal anti-DNA antibody of NZB/W Fl 
origin and found 8/13 MCA with similar ligand 
specificities shared a common idiotype.
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5. Human monoclonal autoantibodies.
Establishing monoclonal autoantibodies directly 
from autoimmune patients has been an attractive 
proposition for a number of reasons. Certain autoantigens 
may be difficult to purify or poorly immunogenic in mice. 
Where they may be used as immunogens in rodents/ the 
immune response may be very different to the autoimmune 
situation. Where murine MCA are available/ it would be 
useful to compare their specificities directly with human 
monoclonal autoantibodies. Rodent models of human 
autoimmune diseases are not always available/ and where 
they are/ they may not be identical to the human 
counterpart. Thus autoantibodies may not have the same or 
even similar specificities as found in human disease. 
Human monoclonal autoantibodies would provide ideal 
reagents for studying idiotypes and hence the origins and 
diversity of the human autoimmune response.
5(i) Difficulties in the production of human MCA.
Human MCA have been the subject of some 
considerable interest in areas of research other than 
autoimmunity. These include blood group and tissue typing 
and diagnosis and therapy in oncology and infectious 
diseases. Despite an intensive research effort into the 
production of human MCA/ progress has been very slow.
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5(ii). Human-human fusions.
In 1980/ Croce et a_l. and Olsson and Kaplan 
independently published work which suggested that 
human-human hybridoma technology might emulate the 
success of rodent monoclonal antibody production first 
reported by Kohler and Milstein five years earlier. 
However/ two serious problems have yet to be overcome 
concerning each of the fusion partners required for 
fusion. The most readily available sources of human 
lymphocytes are peripheral blood and lymph node tissue. 
The percentage of B-lymphocytes producing specific 
antibody from these is likely to be very small compared 
to the cells available from the spleen of an optimally 
immunised mouse. To some degree this can be overcome by 
in vitro immunisation (Osband e_t al^ . 1981/ Foon et: al. 
1983/ Cavagnaro and Osband 1983)/ pre-stimulation with 
polyclonal activators (Chiorazzi ejt al^ . 1982/ Shoenfeld 
et a l . 1982) or pre-selection of antigen specific cells 
(Kozbor and Roder 1981).
Problems with the human cell lines were 
apparent from the start. It was two years before the 
success of 1980 was repeated/ many workers being unable 
to produce hybridomas partly because of mycoplasma 
contamination of myeloma stocks (Sikora and Munro-Neville
1982). Different human myeloma lines and lymphoblastoid 
lines were adapted to continuous culture as HAT sensitive
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variants. By 1983 Kozbor and Roder were able to review 
the performance of ten such lines as suitable partners 
for the production of hybridomas. The ideal cell line 
should have good growth characteristics/ be robust in 
culture/ fuse with high efficiency/ support the secretion 
of large amounts of lymphocyte-derived immunoglobulin 
while secreting none of its own,and generate hybrids that 
clone easily and are stable over long periods of time. A 
number of such rodent lines are available but not one 
human line is available which meets these criteria (Foon 
et al. 1983/ Kozbor and Roder 1983).
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Table 3.1 Human and Rodent Fusion Partners.
Cell line Cell Type Ig secreted Fusion Freq.(xlO )
(Human)
SKO-007 Myeloma IgE 3.7
TM7-H2 Myeloma IgG N.D.
DHMC Myeloma IgG 1-10
GM1500 LCL IgG 1.8
KR4 LCL IgG 3-11
HMy-2 LCL IgG <1
GM0467.3 LCL IgM 2.2
H351.1 LCL IgM 2.2
UC729-6 LCL IgM N.D.
GM4672 LCL IgG N.D.
(Mouse) 
P3-X63Ag8 Myeloma IgG -10
NSl tt light chains IV
X63 If none It
Sp2/0 IV II VI
NSO If If II
(Rat)
Y3.Ag.123 tfl light chains n
YB20.Ag20 IV none VI
(From Kozbor and Roder 1983/ Galfre and Milstein 1981).
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5(iii). Human-mouse fusions.
A number of workers have used murine myelomas 
in fusions with human lymphocytes to yield human-mouse 
heterohybrids which secrete human immunoglobulins. As 
early as 1973/ Schwaber and Cohen reported the fusion of 
the mouse myeloma TEPC-15 with human PBL from which they 
cloned a hybrid secreting both human and mouse 
immunoglobulins. Levy and Dilley (1978) fused 
non-secreting, human neoplastic B-cells with the mouse 
myeloma P3-X63-Ag8 to produce hybrids which secreted, in 
large quantites, human immunoglobulin of the same light 
chain type as found on the surface of the neoplastic 
parent lymphocyte.
Human-mouse hybrids preferentially segregate 
human chromosomes (Croce et al. 1974, 1980), and as two 
human chromosomes carrying the rearranged genes for human 
light and heavy immunoglobulin chains must be retained, 
this technique is generally thought to be unsatisfactory. 
The instability problem may not be as great as is 
generally thought, for reasons discussed later in the 
thesis. In view of the disadvantages of human fusion 
partners, a degree of hybrid instability may be an 
acceptable compromise. Human monoclonal antibodies, using 
human-mouse fusions, have been successfully produced 
against the Forssman antigen (Nowinski ejt a_l. 1980), 
human cellular antigens (Schlom et_ al. 1980, Cote et al.
1983), keyhole limpet heamocyanin (Lane et al. 1982), and
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tetanus toxoid (Kozbor et a l . 1982/ Butler et a l . 1983). 
5(iv). The EBV technique.
Although not involving fusion of cells to form 
hybrids, a third method of producing human MCAs should be 
mentioned here. This involves the transformation of 
lymphocytes by Epstein-Barr virus. EBV is a lymphotropic 
herpesvirus capable of polyclonal activation of normal 
human B-lymphocytes and converting them into immortal 
cell lines (Rosen elt al. 1979/ Miller and Lipman 1973). 
EBV transformed cells carry multiple copies of the viral 
genome and express an EBV specific nuclear antigen/ EBNA. 
Steinitz et aJL. (1977) were the first to use EBV to 
produce B-cell lines secreting pre-defined antibody/ in 
this case to the synthetic hapten NNP. They collected 
lymphocytes from normal volunteers who demonstrated high 
natural antibody titres to NNP/ and selected for antigen 
receptor positive cells by rosetting with NNP-coupled 
erythrocytes. The lymphocytes were infected with EBV and 
after 4 weeks permanent lines were established which 
secreted anti-NNP antibodies. EBV transformed lines have 
now been made secreting antibodies to TNP (Kozbor e_t a l . 
1979)/ tetanus toxoid (Zurawski et al. 1978)/ Rhesus 
antigen D (Boylston et al_. 1980/ Crawford et^  al^ . 1983)/ 
phosphorylcholine (Yoshie and Ono/ 1980)/ rheumatoid 
factor (Steinitz et aJ. 1980), and acetylcholine receptor 
(Kamo et al. 1982). After transformation the lines remain
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oligoclonal for some months; they may be difficult to 
clone and often lose the antibody production (Zurawski et 
a l . 1978/ Kozbor and Roder 1981). Often only small 
amounts of antibody are secreted (Kozbor and Roder 1983). 
At the begining of this study the marmoset cell line 
B95-8 used as a source of EBV in many different 
laboratories was found to be contaminated with mycoplasma 
(Dr. B.Bradley/ personal communication).
5(v ). Successes in human monoclonal autoantibody 
production.
Comparatively little has been published on the 
successful production of human monoclonal autoantibodies. 
Hirano et: a^ L. (1980) established autoantibody producing B 
cell lines by transformation of autoimmune patient's PBL 
with EBV. Four lines were established/ two of which 
produced anti-nuclear factor antibodies/ and one produced 
anti ssDNA and anti dsDNA antibodies. It was not certain 
that the antibody products were monoclonal/ however.
Shoenfeld ejt al. (1982) were the first to 
report the production of truly monoclonal human 
autoantibodies by the hybridization technique. They fused 
PBL from 2 SLE patients/ 1 cold agglutinin patient and 
two patients with atopic allergy with the human cell line 
GM 4672. They isolated 6 hybrids secreting monoclonal 
anti-platelet antibodies/ 7 secreting anti-ssDNA 
antibodies/ and 7 hybrids secreting monoclonal cold
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agglutinins*
Eisenbarth et^  a!L. (1982) fused PBL from a 
patient with type I diabetes mellitus with the human cell 
line GM 1500/ They isolated a hybrid which secreted a 
MCA which had similar reactivity to pancreatic islet 
cells as found in the patients serum.
Kamo et al. (1982) established a human B cell 
line by EBV transformation which secreted a MCA to AChR. 
The B cells were obtained from the thymus of a patient 
with MG/ and the MCA bound rat and human muscle receptor 
but not receptor from the electric organs of Narke 
japonica. Passive transfer of the MCA into rats was 
demonstrated to induce muscle weakness and 
electromyographic changes characteristic of MG.
Valente et^  al^ . (1982) obtained four human MCA 
against the receptor for thyroid stimulating hormone 
(TSH) by fusing the mouse myeloma NSl with PBL from 
patients with Graves disease. Two of these were found to 
stimulate thyroid function in several assay systems.
These 2 MCA , as well as the 2 non-stimulatory MCA/ 
specifically inhibited TSH binding to cultured thyroid 
cells.
Satoh ej: al^ . (1983) fused both mouse and human 
myelomas with PBL from patients with insulin-requiring 
diabetes and other autoimmune abnormalities. The 
hybridoma products were screened by indirect 
immunofluorescence against tissue from a variety of human 
organs. They found 7 MCA which reacted with antigens in
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multiple endocrine organs. This may partially explain 
multiple organ autoimmune diseases; an antigenic 
determinant that occurs in several different organs can 
account for the apparent multiplicity of the 
autoantibodies in such disorders.
The potential usefulness of human MCA in the 
study of autoimmune disease is only just starting to be 
realised. It seems likely that the keen interest being 
shown in human MCA in many fields of pure and applied 
immunobiology will overcome the technical problems that 
have plagued their production so far.
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Aims of this study.
As has been discussed/ human MCA have potential 
applications in many fields/ including the diagnosis and 
treatment of infectious diseases/ blood and tissue 
typing/ oncology and the study of human immune responses. 
The technology for the production of human MCA lags 
behind that of its rodent counterpart. Optimal systems 
for the production of human MCA have yet to be 
established. The prospective producer of human MCA is 
faced with a number of alternative methods and 
variations. Antibody-secreting lines can be produced by 
EBV transformation of human lymphocytes/ by cell fusion 
to form hybridomas/ or by a combination of the two 
(Kozbor and Roder/ 1983). If a fusion method is chosen/
the choice between human and mouse fusion partner has to
be made/ and then one selected from the many now 
available. The first aim of this project was to evaluate 
the performance of one human fusion partner/
LICR—LON—HMy2/ and two mouse partners/ NSl and
X63-Ag8.653/ in the production of human MCA by the 
PEG-induced fusion method. The LICR-L0N-HMy2 line was 
chosen as it had been shown to successfully produce human 
hybrids (Edwards et a_l. 1982)/ and was the only 
HAT-sensitive human lymphoblastoid or myeloma line freely 
available at the beginning of this study. NSl and X63 
were chosen as well established mouse myelomas of proven 
use in the production of murine MCA. In addition/ NSl had
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been shown to be useful in the production of human 
immunoglobulin-secreting hybrids (Schlom et^  al^ . 1980, 
Nowinsky £t a_l. 1980, Wunderlich et^  a_l. 1981),
The production of human MCA can be divided into 
two component problems; the first is that of establishing 
stable, human immunoglobulin-secreting cell lines, and 
the second of establishing lines secreting antibodies of 
pre-defined specificity. Establishing specific 
antibody-secreting lines from rodents is critically 
dependent on an effective immunisation schedule and 
timing of fusion following a final boost. Whereas this 
can be completely controlled in animal work, there are 
far fewer circumstances in humans where this is possible. 
Autoimmune patients provide a population of 'naturally 
immunised' subjects which overcome ethical problems of 
deliberate immunisation. In addition, MCA have potential 
uses in the study of both the autoantigens and the 
autoantibodies in autoimmune disease. In MG, murine MCA 
to the AChR have been extremely useful in the detailed 
study of the auto-antigen. Human MCA to the AChR would be 
useful to study the human response to the autoantigen in 
terms of antibody specificity, idiotypic diversity and 
the relative pathogenicity of individual antibodies. In 
SLE, in addition to the interest in the autoantibodies, 
MCA would be of considerable use in probing the structure 
and function of many autoantigens. The ribonucleoproteins 
recognised by certain SLE sera are of particular 
interest, and murine MCA have not been readily
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forthcoming/ probably because of the poor immunogenicity 
of these molecules.
The second aim of this project was to examine 
the possibility of producing human MCA by fusion of PBL 
from autoimmune patients with demonstrable serum 
autoantibodies. Specifically the the questions asked were 
could hybrids be made from MG PBL which secreted 
anti-AChR antibodies/ and similarly could anti-nRNP/ Sm/ 
Ro and anti-La secreting hybrids be formed from PBL of 
SLE patients? If such MCA could be made they would then 
be characterised.
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Materials.
1. Cells and cell culture materials.
The HAT sensitive/ human lymphoblastoid cell 
line LICR-L0N-HMy2 was a gift from Dr P.A.W. Edwards/ 
Ludwig Institute for Cancer Research/ Surrey.
The HAT sensitive mouse myeloma NSI/l.Ag4.1 was 
a gift from Dr G. Farrar/ Biochemistry Dept. University 
of Bath.
The HAT sensitive mouse myeloma X63-Ag8.653 and 
the human epithelial cell line HEp-2 were obtained from 
Flow Laboratories/ Scotland.
Normal human skin fibroblasts from human 
foreskin/ supplied at passage 1 1 / were a gift from M. 
McAleer and Dr S. Moss/ Dept, of Pharmacy/ University of 
Bath.
Mycoplasma-free/ marmoset cell line B95-8 and 
EBV transformed human tonsil B cells were a gift from Dr 
M.D.Melamed/ M.R.C. Cambridge.
Sterile media and supplements; RPMI 1640/ BME 
(modified) with Earle's salts/ 'myoclone' FCS/ NCS/ 
L-glutamine (200mM)/ sodium pyruvate (100mM)/ 50X HAT/
50X HT concentrates/ and disposable plasticware were 
obtained from Nunc Gibco/ Flow Laboratories and Sterilin.
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2. Immunological reagents.
Alkaline phosphatase conjugated antibodies and 
human IgA (from colostrum) were obtained from Sigma.
Goat anti-whole human serum and goat anti-whole 
mouse serum were obtained from Miles.
Sheep anti-human IgG and sheep anti-human IgM 
were a gift from Prof. G. Stevenson/ Tenovus 
Laboratories/ Southampton.
Goat anti-polyvalent human immunoglobulins was 
a gift from H. Lotwick/ Dept, of Biochemistry/ University 
of Bath.
3. Radio-isotopes.
125 I (carrier free) was obtained from the 
Radiochemical Centre/ Amersham/ Bucks.
4. Chromatography media.
Protein A Sepharose CL-4B/ Sepharose 4B and 
DEAE Sepharose CL- 6 B were obtained from Pharmacia. AcA 34 
Ultrogel was obtained from LKB.
5. Buffers and solutions.
Buffers and solutions were made with Analar 
grade reagents and double distilled water. Where not
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detailed in the text, buffers and solutions were prepared 
according to *Data for Biochemical Research* (Dawson et 
al. 1974).
6 . Instruments.
Ultracentrifuge model L5-65 was supplied by 
Beckman. Bench centrifuges and micro-centaur centrifuge 
were from M.S.E. UV absorbtions were measured by a Cecil 
CE 212 variable wavelength monitor and a manual ELISA 
reader fitted with a 405 nm filter/ from Gilford 
Instruments. A model 1280 Ultrogamma from LKB was used 
for gamma radiation counting. A Zeiss Orthoplan light 
microscope with incident UV facility was used for cell 
counting and immunofluorescent studies.
7. General reagents.
Trypsin (type XI) prepared from bovine 
pancreas/ DNA (from calf thymus)/ Heparin/ 
2-mercaptoethanol/ 8 -azaguanine/ DMSO/ Cyanogen bromide/ 
Colcemed/ Morpholinopropanesufonic acid/ DTT/ Vinblastine 
sulphate/ Cytochalasin B/ Hoechst 33258/ DNase 1/ BSA and 
P-nitrophenyl phosphate were from Sigma.Iodoacetimide/ 
Nigrosine/ Nonided P-40 were from B.D.H. chemicals. 
Aprotinin was from Bayer/ Germany. PEG 4000 (GK) was from 
Merck. Benzoquinonium chloride was a gift from Sterling 
Winthrop/ Renssalaer/ N.Y . , U.S.A.
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All other reagents were from Sigma/ B.D.H. / 
Fisons or Aldrich.
8 . Patients and antigens.
Peripheral blood samples from SLE and MCTD 
patients were obtained with the co-operation of Dr P. 
Maddison/ Royal National Hospital for Rheumatic Disease/ 
Bath.
Peripheral blood was collected from myasthenic 
patients with the co-operation of Dr T.Wallington/ Blood 
Transfusion Centre/ Southmead Hospital/ Bristol/ Dr 
Cambell/ Bristol Royal Infirmary and Dr Wakefield/ Royal 
United Hospital/ Bath.
Ro and La antigens/ purified by affinity 
chromatography from human spleen extract/ calf thymus 
respectively/ were gifts from Dr P. Skinner/ R.N.H.R.D. 
Bath. Sm and nRNP antigens/ purified by affinity 
chromatography from calf thymus extract were gifts from 
D. Brennand/ Dept. Biochemisty/ University of Bath.
Methods.
Cells;
1. Isolation of peripheral blood lymphocytes.
20ml of freshly drawn venous blood was diluted 
1:1 with PBS containing 40 I.U. ml ^ heparin. 10 ml
volumes were layered onto 5 ml volumes of "Lymphoprep" in
15 ml siliconised glass centrifuge tubes/ according to
the makers* instructions. The gradients were centrifuged
at 200xg (at the interface) for 30 min at room
temperature. Mononuclear cells were aspirated from the
interface and washed twice by centrifugation in PBS (20
min at 400xg/ then 5 min at 200xg). Cells were
resuspended in complete RPMI 1640 (see ‘maintenance of
cell lines') and a small sample was stained with an equal
volume of 10mg% Gentian Violet in 3% Glacial acetic acid.
After counting in a haemocytometer counting chamber/ the
6 —1remaining cells were diluted to 1 0  ml and stored for 
up to 24 h at 37°C in 5% CO 2  until use.
2. Depletion of T-lymphocytes by AET-SRBC rosette 
gradient centrifugation.
T-cell depleted PBL were obtained by the method 
of Madsen et . a_l. (1980). SRBC of less than two weeks of 
age were suspended in 140 mM AET/ pH 9.0 for 15 min at 
37°C. They were then washed by centrifugation five times 
in isotonic saline at 500xg. AET-SRBC were stored up to 
one week in PBS containing 40% heat inactivated FCS at 
4°C.
3 ml of cell suspension in PBS at a density of 3x10** ml  ^
was added to 3 ml of 1% v/v AET-SRBC in 40% FCS and 
cooled to 4°C for 30 min. They were then centrifuged at 
200xg for 15 min at room temperature. The supernatant was
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removed and the pellet overlaid with 5 ml of Percoll 
adjusted to a specific gravity of 1.078 with PBS. 1 ml of 
PBS/FCS was then layered over the Percoll. The tubes were 
centrifuged at 550xg for 20 min at room temperature. The 
non-rosetted cells (non-T cells) were collected from the 
interface and washed. These were found upon re-rosetting 
to be contaminated with < 3% rosetting cells.
3.Transformation of lymphocytes by EBV.
Isolated human PBL/ depleted of T cells/ were
suspended in undiluted B95-8 culture supernatant at 1 x
10^ ml After incubation for 1 h at 37°C with constant
agitation/ the cells were spun down and resuspended in
5 -1fresh/ complete RPMI/ at a concentration of 2 x 10 ml 
Cells were then cultured at 37°C in 5% CO 2  and fed and 
expanded when necessary.
4.Maintenance of cell lines.
Three cell lines were used as fusion partners; 
two mouse myelomas (NSl/ X63-Ag8.653.) and one human 
lymphoblastoid line (LICR-L0N-HMy2). They were all grown 
in RPMI 1640 supplemented with 10% FCS/ 2mM. glutamine/
_5
5x10 M 2-mercaptoethanol/ and 60 yg ml tylocine/ in an 
atmosphere of 5% CO 2  in air/ at 37°C. Under these 
conditions the cell lines had doubling times of 18-24 h/ 
and were maintained in log phase growth by daily
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sub-culturing. Prior to fusions/ the viability of the 
cells (determined by nigrosine dye exclusion) exceeded 
95%. Periodically 8 -Azaguanine was included in the 
culture medium at 20 yg ml ^ to eliminate any HAT 
insensitive variants.
Human epithelial cell line HEp-2 and normal 
human fibroblasts were grown as monolayers in B.M.E. with 
Earle's salts supplemented with 10% NCS/ 2mM glutamine 
and 60 yg ml ^ tylocine/ in an atmosphere of 5% CO 2  at 
37°C. When cells had grown to confluency/ they were 
harvested by brief trypsinisation with 0.025% crude 
trypsin in PBS/ and new cultures initiated at a split 
ratio of 1:40 for HEp-2 and 1:4 for fibroblasts.
B95-8 cells were grown as monolayers in
5 -1complete RPMI. Cells were seeded at 1 x 10 ml . For the 
production of virus/ cells were allowed to grow for 7-10 
days and the supernatant harvested/ filtered through a 
0.45 m filter/ and stored at 4°C for up to 1 week. New 
cultures were initiated from confluent/ but not overgrown 
flasks following brief trypsinisation as for human 
fibroblasts.
5. Screening cell lines for Mycoplasma contamination.
Cell lines were periodically checked for 
mycoplasma contamination by Hoechst 33258 staining as 
described by Freshney (1983). This stain binds 
specifically to DNA/ and mycoplasmas can be detected
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under a UV microscope by their characteristic particulate 
or filamentous pattern on the cell surface.
(a). Monolayer cultures;
Cells in mid-log phase growth were seeded on 
multispot microscope slides and allowed to attach 
overnight at 37°C in a humidified, gassed incubator. The 
slides were then rinsed in PBS followed by acetic 
acid-methanol (1:3) diluted with an equal volume of PBS. 
The cells were fixed for 10 min in pure acetic 
acid-methanol, then rinsed thoroughly with distilled 
water. Slides were immersed for 10 min in PBS containing 
50 ng ml”'*' Hoechst 33258. After rinsing with water, the 
cells were mounted in buffered glycerol (Glycine 0.42g, 
NaOH 0.02g, NaCl 0.51g, E^O 30 ml, Glycerol 70 ml), and 
examined under an epifluorescent microscope, using a 
Zeiss UG-1 filter and dichroic mirror for excitation, and 
K400, K460 filters for emission.
(b) Suspension cultures:
g
5x10 cells in mid log phase growth were washed 
with PBS by centrifugation (5 min 200xg). The pellet was 
resuspended in 5 ml of PBS and 5 ml of acetic 
acid-methanol added with constant stirring. The cells 
were pelleted by centrifugation then resuspended in pure 
acetic acid-methanol and fixed for 10 min. The cells were
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pelleted by centrifugation and resuspended in 300 yl of 
fresh fixative. 50 yl of this suspension was dropped onto 
a cold microscope slide soaked in methanol. After drying 
in air/ the cells were stained as for monolayer cultures.
6 . Viability of cells.
Cell viability was determined by nigrosine dye 
exclusion. Cells in suspension were mixed with an equal 
volume of 0.2% nigrosine in PBS and incubated for 5 min 
at room temperature. The cells were counted in the 
counting chamber of a haemocytometer. Dead cells took up 
the stain and appeared black.
7. Preparation of mouse peritoneal cell feeder layers.
Mice were killed by cervical dislocation and
the abdominal skin removed to reveal the peritoneal wall.
5 ml of sterile PBS was injected into the peritoneal
cavity and/ after gentle massage/ removed with a pasteur
pipette via a small incision above the liver. Cells were
60irradiated with 2000 Rads from a Co source and 
centrifuged for 5 min at 200xg. The cells were 
resuspended in complete RPMI medium/ diluted 
appropriately and transferred to 96 well trays such that
4
each well received 10 cells in 50 yl. The trays were 
kept at 37°C in a humidified atmosphere of 5% CO 2  in air, 
for 24 h before use.
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8 . Fusions.
PBL and myeloma cells were added together in a 
40 ml siliconised glass centrifuge tube/ diluted with PBS 
and spun to a common pellet for 10 min at 200xg. The 
ratio of PBL to myelomas was between 1:1 and 2:1. After 
loosening the pellet/ 1 ml of 50% PEG in PBS was added 
dropwise over one min with constant agitation. Agitation 
was continued in a water bath at 37°C for 90 S/ after 
which the cells were slowly diluted with PBS at room 
temperature/ then gently resuspended in complete RPMI 
1640/ and distributed in 96 well trays pre-seeded with 
mouse peritoneal cells/ such that each well received
5
1x10 myeloma cells in 100 yl of medium. After 24 h 
incubation/ 100 yl of medium containing 2 x HAT was 
added. In fusions with EBV-transformed lymphocytes/ 1 yM 
oubain was included in the medium to prevent the 
outgrowth of unfused lymphoblastoid lines. Wells were 
examined after 7 days when feeding was started by 
replacing half the medium with fresh 1 x HAT. Feeding was 
repeated every two or three days. Wells positive for 
growth were screened for immunoglobulin or antibody 
production when cells covered half the bottom of the 
well. Hybrids of interest were cloned directly from the 
96 well trays. HAT selection was maintained for three 
weeks post fusion and the cells passaged through HT 
medium before culturing in standard medium.
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9. Cloning of hybrids.
Hybrids were transferred singly from a culture 
in log phase growth/ by use of a micromanipulator and 
microscope/ to individual wells of a 96 well tray 
pre-seeded with feeder cells. To ensure only single cells 
were transferred/ cells were only picked up when alone in 
the field of a high power lens/ and expelled into an 
intermediate vessel for examination before being moved to 
the final well.
10. Cryopreservation of cells.
Cells in log phase growth were pelleted by 
centrifugation. The pellet was resuspended in complete
7
medium such that the concentration did not exceed 2 x 1 0  
ml The suspension was then chilled on ice for 15 min 
and an equal volume of cold freezing mixture (20% DMSO/ 
40% FCS/ 40% RPMI) was added with stirring. 1 ml aliquots 
were transferred to freezing ampoules/ placed in the 
vapour phase of liquid nitrogen overnight at a freezing 
rate of -1°C per min/ then stored in the liquid phase 
until required. For recovery of frozen cells/ ampoules 
were rapidly thawed at 37°C/ washed once by 
centrifugation/ then cultured at high density until fully 
recovered.
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11. Preparation of cell monolayers for 
immunofluorescence.
Confluent cultures of HEp-2 or human 
fibroblasts were trypsinised and suspended in complete 
medium. 40 yl aliquots were then transferred to each well 
of a 1 0  spot microscope slide/ previously heat 
sterilised. The slides were placed in clean petri dishes 
and incubated overnight at 37°C in a humidified 
incubator. After a 5 min wash in PBS the slides were 
immersed in ice cold acetone for 1  min and allowed to dry 
in air. Alternatively some slides were fixed in 2% 
paraformaldehyde in PBS for 15 min at room temperature 
immediately before the acetone step. Fixed slides were 
stored dessicated at -20°C until required.
1 2 . Ijn situ fractionation of cells.
Cells grown as monolayers on microscope slides 
were fractionated iji situ by the method of Staufenbiel 
and Deppert (1984). Cell monolayers were washed three 
times with lOmM Morpholinopropanesulfonic acid/ pH 6.2; 
lOmM NaCl; 1.5mM M g C ^ ;  30 yg ml ^ Aprotinin; 10% 
glycerol (Kern matrix buffer/ KM). For the first 
extraction step/ the cells were incubated at 4°C with KM 
buffer containing 1% NP40/ ImM EGTA and 5mM DTT. After 3 
min the extraction buffer was replaced with fresh 
extraction buffer and incubation continued for 27 min.
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The slides were washed three times with buffer A and 
incubated for 15 min at 37°C with KM buffer containing 
50 y g  ml”* DNase 1. After washing/ the slides were 
incubated for 30 min at 4°C in KM buffer containing 2M 
NaCl/ ImM EGTA and 5mM DTT. The slides were then washed 
in KM buffer. Slides were fixed after each step of the 
extraction procedure for 1  min in cold acetone and stored 
at -20°C until required.
13. Drug disarrangement of cytoskeletons.
HEp-2 cells or fibroblasts were grown overnight 
on microscope slides. The medium was aspirated from the 
slides and the cells were treated with medium containing 
either 0.5 yg ml”* Colcemid for 24 h, 10 yg ml”* 
vinblastine sulphate for 4 h/ or 10 yg ml * cytochalasin 
B for 30 min. The cells were rinsed with PBS and fixed in 
cold acetone for 1 min. The slides were stored at -20°C 
until required.
14. Chromosome Analysis of cells.
Hybrids were harvested in log phase growth and 
6 —1suspended at 1 0  cells ml” in complete medium containing 
0.1 yg ml * Colcemid for 4 h. Hypotonic treatment with 
0.075M KCl for 12 min was followed by fixation with 1:3 
acetic acidrmethanol. After two changes of fixative/ the 
cells were dropped on cold/ methanol soaked slides and
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air dried. Chromosomes were counted after staining for 10 
min with 2% Giemsa in PBS/ or following Hoechst staining 
as described under ’Screening for Mycoplasma*. At least 
forty mitotic figures were counted for each line.
General Methods:
15. Preparation of immunoglobulins.
Human IgM was prepared from Waldenstrom 
macroglobulin sera according to the method of Jehanli and 
Hough (1981). Serum samples were applied to a column of 
Ultrogel AcA 34 and eluted with 0.1M Tris/HCl/ 0.15M 
NaCl/ 0.02% NaN^/ pH 8.0. IgM containing fractions were 
located by double diffusion with sheep anti-human  ^ chain 
antiserum. Fractions containing IgM were pooled/ 
concentrated by ultrafiltration and dialysed against 
0.05M Na 2 HPO^/citric acid buffer/ pH 6 .8 . Ion-exchange 
chromatography of the partially purified IgM was carried 
out on a 2.5 x 40 cm column of DEAE Sepharose CL 6 B/ 
equilibrated with 0.05M Na 2 HP 0 ^/citrie acid buffer/ pH 
6 .8 . The column was eluted with 300 ml of starting buffer 
followed by a linear gradient made from starting buffer 
(300 ml) and 0.1M Na 2 HP 0 ^/citrie acid/ pH 5.0 (300 ml). 
Residual bound protein was removed from the column with 
0.4M NaCl. Fractions were examined by 
immunoelectrophoresis using sheep anti-whole serum 
proteins. Fractions giving a single precipitin arc
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corresponding to IgM were pooled/ dialysed against 0.1M 
Tris/HCl/ 0.15M NaCl buffer pH 8.0/ and concentrated to 
1 0  mg ml
Human IgG was prepared from pooled normal human 
serum by affinity chromatography on protein-A sepharose 
CL4B. Serum was applied to the column of sepharose and 
washed with PBS until the optical density was back to 
baseline. IgG was then eluted with 0.2M citric 
acid/phosphate buffer/ pH 3.2 containing 0.5M NaCl. The 
elution was monitored by UV absorbtion at 280 nm. The IgG 
was collected and dialysed against PBS and stored at 
- 2 0 ° C •
Mouse IgG was prepared from serum by affinity 
chromatography on protein-A sepharose CL4B. The pH of the 
serum was adjusted to 8.0 with 0.1M NaOH/ and diluted 1:1 
with 0.1M phosphate buffer/ pH 8.0. The serum was applied 
to the column and washed until no more protein was washed 
through. The procedure was then identical to the 
preparation of human IgG.
Purity of immunoglobulins was confirmed by 
immunoelectrophoresis and SDS-PAGE.
16. Protein determination.
Protein concentrations were determined by UV 
absorbtion at 280 nm. The extinction coefficients (E2q o  ^
were taken from Johnstone and Thorpe (1982): IgG 13.6/ 
IgM 11.8/ secretory IgA 12.6. For other proteins the
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following formula ( taken from the same source) was used: 
Protein conc.(mg ml ^)= 1.55 x absorbance at 280nm - 
0.77 x absorbance at 260nm.
17. Affinity columns.
Sepharose 4B was activated by cyanogen bromide 
according to the method of March et^  al^ . (1974). 20g of 
washed sepharose was suspended in 40 ml of 2M and
stirred slowly. 2 g of cyanogen bromide/ dissolved in 2  ml 
of acetonitrile was added at once to the slurry on ice# 
and stirring was continued for 2 min. The mixture was 
then poured into a coarse sintered-glass funnel and 
washed with cold water and 0.1M NaHCO^. Protein to be 
coupled was dissolved in 20 ml of 0.1M sodium bicarbonate 
buffer, pH 8.0/ and added to the activated gel. The 
suspension was stirred overnight at 4°C, washed with PBS 
and unreacted sites blocked by incubation in 1M 
ethanolamine/ pH 8.0 for 1 h. After washing in PBS/ 0.5M 
acetic acid and PBS again/ the coupled gel was stored in 
PBS containing 0.02% sodium azide at 4°.
18. Affinity isolation of antibodies.
(a) Anti- ychain antibodies:
Sheep antiserum to human IgM was passed down a 
column of IgM-sepharose. Anti-IgM antibodies were eluted
with ice cold 0.5M acetic acid. The protein was 
immediately dialysed against PBS. Denatured protein was 
removed by centrifugation (30 min at 10/000xg). 
Anti-light chain activity was removed by two passages 
through an IgG-sepharose column. The pure antibody was 
stored at 4°C in PBS at 1.0 mg ml"*.
(b) Anti- ychain antibodies:
Sheep antiserum to human IgG was passed down a 
column of IgG-sepharose. Anti-IgG antibodies were 
prepared as described above. Anti-light chain activity 
was removed by passage down an IgM(ic) column and an 
IgM(x) column. The pure antibody was stored as above.
19. SDS Polyacrylamide gel electrophoresis.
SDS-PAGE was performed according to the method 
of Laemmli (1970) using a slab gel apparatus. Standards 
used were alpha-2-macroglobulin (Mr 174/000), human 
chain (Mr 74/000)/ BSA (Mr 68/000)/ human chain (Mr 
50/000)/ ovalbumin (Mr 43/500)/ human light chain (Mr 
25/000)/ and ribonuclease A (Mr 13/500).
20. Radio-iodination of g-BTX.
a —BTX was labelled to a high specific activity
125
with I by the method of Urbaniak et al. (1973). All
procedures were carried out at room temperature/ and
unless otherwise stated all solutions were made in 0.05M
125potassium phosphate pH 7.5. Carrier free Na I was
stored at ambient temperature# and was used for up to
125three weeks after the quoted reference date. Na I (100 
mCi ml”^/ 10 pi) in dilute NaOH was added to a-BTX (1 yg, 
20 yl). Chloramine T (0.5% w/v# 10 yl) was then added and 
the solution stirred for 1  min# after which sodium 
metabisulphate (0.016% w/v# 750 yl) and potassium iodide 
(1% w/v# 10 yl) were added. The reaction mixture was 
immediately applied to a Sephadex G25 column equilibrated 
with 0.01M potassium phoshate pH 7.4 containing 1% BSA# 
and eluted with the same buffer. 1  ml fractions were 
collected and 5 yl aliquots counted in an LKB Ultrogamma 
counter. The radioactive protein peak fractions were 
pooled# and the specific activity of the labelled toxin 
calculated assuming 1 0 0 % recovery of protein.
21. Preparation of crude human AChR.
A modification of the method described by 
Sb^fhenson et al. (1981) was used. Adult human limb muscle 
was obtained from patients undergoing amputation because 
of vascular abnormalities or diabetic gangrene. In the 
latter case only limbs in which gangrene was confined to 
the toes were. used. The muscle# mainly gastrocnemious# was 
coarsely chopped and frozen immediately in liquid 
nitrogen. All subsequent operations were carried out at
-94-
4°C and buffers contained 1 mM PMSF/ 0.02% sodium azide 
and 1 mM EDTA in 0.01 M potassium phosphate pH 7.4. 
Thawed muscle (200-300 g) was homogenised in a Waring 
blender for 1 min at full speed in 5 vol of buffer 
containing 0.1 mM benzethonium chloride/ 10 yg ml  ^
soyabean trypsin inhibitor/ 1 mM benzamidine 
hydrochloride/ 100 y g ml  ^ bacitracin/ 50 mM NaCl and 10 
mM iodoacetamide. After centrifugation at 20/000xg for 1 
h/ the pellet was homogenised in 1  - 2  vol of the above 
buffer containing 2% v/v Triton X-100/ and was extracted 
by paddle stirring for 3 h. The extract was centrifuged 
for 1  h at 1 0 0 /0 0 0 xg and the supernatant containing 
solubilised receptor stored at 4°C until assay and use.
Assays.
2 2 .Assay for human immunoglobulin.
Supernatants were screened for production of 
human immunoglobulin by an enzyme-linked immunoassay. 
Gilford EIA cuvettes were coated with 250 yl of PBS 
containing 1 0  yg ml ^ anti-human immunoglobulin heavy 
chain specific antibodies for 24 h at 4°C. Cuvettes were 
then blocked by incubation with PBS containing 1.0% 
casein for 15 min. After washing with PBS containing
0.05% Tween 20/ 50 yl of culture supernatant and 200 yl 
of PBS-Tween were added to each well and incubated for 1 
h at 37°C. The cuvettes were washed and 250 yl of
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alkaline phosphatase conjugated goat anti-human \i, y, a , 
k/ or Xchain specific antibody (diluted 1:1000 in 
PBS-Tween) was added to each well. After 1 h incubation 
at 37°C/ the cuvettes were washed and 250 yl of 
p-nitrophenyl phosphate (ling ml in 1 0 % diethanolamine 
buffer (pH 9.6) was added to each well. Colour changes 
were monitored by a Gilford EIA reader with a 405nm 
filter.
23. CELIA for estimation of human immunoglobulins.
To determine immunoglobulin concentrations/ a 
competitive enzyme-linked assay was employed. Cuvettes 
were coated overnight at 4°C with human IgM/ IgG or IgA 
at 200 ng ml ^ in 0.05M carbonate buffer pH 9.6. Serial 
dilutions of standard immunoglobulins and appropriately 
diluted culture supernatants in PBS-Tween were 
transferred to LP3 tubes (Luckhams). An equal volume of 
alkaline phosphatase conjugated antibody (1 : 1 0 0 0  in 
PBS-Tween) was added and the tubes incubated for 1 h at 
37^C. 250 yl of the mixture was then added to the 
cuvettes previosly blocked and washed as before. The 
cuvettes were incubated/ washed and substrate added as 
above. A standard curve was constructed by expressing the 
A 4 0 5  of the wells containing standard Ig as a percentage 
inhibition when compared to the control wells incubated 
with conjugate alone.
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24. ELISA for RF and antibodies to Ro, La/ nRNP/ Sni/ DNA.
Gilford cuvettes were coated overnight at 4°C 
with poly-L-lysine in PBS at 50 yg ml After washing 
three times with PBS-Tween/ antigen was added at 10 yg 
ml ^ in PBS. Cuvettes were incubated overnight at 4°C. 
After washing three times with PBS-Tween/ unoccupied 
sites were blocked by incubation for 30 min at room 
temperature with 1% casein in PBS. 250 yl of culture 
supernatant diluted 1:1 in PBS-Tween was added to each 
well and incubated overnight at 4°C. The cuvettes were 
washed three times with PBS-Tween and then 250 yl of the 
appropriate anti-human heavy chain specific 
antibody-alkaline phosphatase conjugate was added. After 
2 h incubation at 37°C/ the cuvettes were washed as 
before an 250 yl of substrate was added. Colour changes 
were monitored on a Gilford EIA reader. Controls included 
standard human reference sera and normal human sera
4
diluted 1:10 m  PBS-Tween/ irrelevant monoclonal 
immunoglobulins in culture medium and culture medium from 
unfused X63-Ag8.653 cells.
25. Assay for AChR.
For the assay of crude AChR preparations/ an
ammonium sulphate precipitation assay was used/ based on
the method of Meunier et al. (1972). Crude receptor (100
125
y l ) was mixed with I-a-BTX (0.5-1.5 nM in 50 y l ) and
incubated for 45 min at room temperature. Saturated
ammonium sulphate solution (133 yl) was added to give a
40% v/v final concentration. The samples were left for 16
h at 4°C/ then 40% ammonium sulphate (1ml) was added and
the samples filtered on Whatman GF/C filter discs. Each
filter disc was washed with 3 ml of 40% ammonium sulphate
and counted on an LKB 1280 Ultrogamma counter. The
specific binding was measured by carrying out all assays
in the presence of 0.01M benzoquinonium chloride (50 yl). 
125The I-a-BTX that remained bound m  the presence of
this competing ligand was defined as non-specifically
bound. The specific binding was defined as that
proportion of total radioactivity that was displaced by
the ligand. Receptor activity was expressed as the 
125molarity of I-a-BTX binding sites.
26. RIA for antibodies to human AChR.
The radioimmunoassay for the detection of
anti-acetylcholine receptor antibodies was a modification
of the method of Lindstrom (1977). Solubilised
acetylcholine receptor from human muscle was incubated
125with a five fold excess of I-a-BTX for 45 min at room 
temperature. 0 . 1  pmol. samples of labelled receptor were 
then transferred to LP3 tubes and each incubated with 
1 0 0 yl of culture supernatant for 2 h at room temperature. 
5 yl of normal human serum was added to each tube followed 
by 50 yl of goat anti-polyvalent human immunoglobulins. A
-98-
precipitate was allowed to form for 2  h at room 
temperature. Samples were then centrifuged at 3000xg for 
1 0  min/ and the pellet washed three times by 
centrifugation with 0.01M potassium phosphate buffer pH 
7.4/ containing 0.15M NaCl. The pellet was counted in an 
LKB 1280 Ultrogamma counter. Control samples were 
pre-incubated with a five fold excess over a-BTX of 
benzoquinonium. The resulting counts were subtracted from 
the test values to give specific counts of 
Ab-toxin-receptor complex precipitated.
27. Indirect immunofluorescence.
Forty yl of culture supernatant were applied to 
a well of fixed HEp-2 cells or human fibroblasts on a 
multispot slide. Control wells received either ANA 
positive or normal serum diluted 1:40 in PBS. Slides were 
incubated for 30 min in a humidified chamber at 37°C. 
After three washes of 5 min in PBS/ 20 y 1 of goat 
anti-polyvalent human immunoglobulins (Sigma)/ diluted 
1:20 in PBS/ was added to each well. The slides were 
incubated for 30 min as before/ washed three times in 
PBS/ and counterstained for 5 min in 0.01% Evans Blue.
The cells were mounted in glycerol and observed 
immediately under a UV microscope fitted with Zeiss 
filter set: (2xKP409/K510/K110).
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1. The fusion of HMy2 with normal PBL.
Six fusions were performed to investigate the 
suitability of this cell line for the production of human 
monoclonal antibodies. PBL were isolated from 20 ml 
volumes of blood, freshly drawn from healthy individuals 
and fused to HMy2 cells as described (chapter 4). Hybrids 
were visible to the naked eye from three weeks after 
fusion/ and wells were scored for hybrid growth at five 
weeks. The results are summarised in table 5.1.
Eleven out of the 20 wells positive for growth 
produced IgM and none produced IgA. All hybrids were 
positive for IgG. As HMy2 produces IgG it was not 
possible from these assays to tell whether any of the 
secreted IgG was derived from the lymphocyte fusion 
partner.
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1 2 . 1  x 1 0 7 192 0
2 2.4 x 10 7 192 2
3 1 . 8  x 1 0 7 180 0
4 2 . 0  x 1 0 7 192 17
5 1.5 x 10 7 150 1
6 2 . 6  x 1 0 7 192 0
Totals 12.4 x 10 7 1098 2 0
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2. The fusion of HMY2 with T-cell depleted PBL.
Immediately after fusion/ the cell population 
plated out is a mixture of autologous/ semi-allogeneic/ 
and allogeneic components/ which might be expected to 
generate cytotoxic immune reactions of parental lymphoid 
cells against the HMy2 line and hybrids. Three fusions 
were carried out to see if the frequency of hybrid 
outgrowth could be improved using T-cell depleted PBL. 
Cells were isolated from 40ml samples of blood/ half were 
T-cell depleted and the other half untreated. Both 
populations were separately fused/ and wells positive for 
growth counted after five weeks. Four wells contained 
hybrids from the unfractionated samples and no viable 
hybrids resulted from the T-cell depleted fractions.
3. Fusion of NSl and X63 with normal PBL
A series of fusions were performed to examine 
the fusion frequency of NSl and X63 myeloma cell lines 
with normal PBL. The results are summarised in tables 5.2 
and 5.3. All fusions yielded hybrids and many hybrids 
produced human immunoglobulins. As the X63 line fused 
with the higher frequency/ this line was used to fuse 
with a series of SLE and MG PBL.
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Table 5.2. Success of fusion of NSl with normal PBL.
Fusion Lymphocytes Wells Wells +ve Wells +ve
fused seeded growth human Ig
1 2.4 x 10 7 192 25 1 1
2 1.9 x 10 7 190 33 9
3 1.7 x 10 7 170 34 5
Totals 6 . 0  x 1 0 7 552 92 25









1 2 . 2 X 1 0 7 192 1 1 1 2 2
2 1 . 6 X 1 0 7 160 96 16
3 2 . 6 X 1 0 7 192 1 2 1 30
4 2 . 0 X 1 0 7 192 119 33
Totals •
CO X 1 0 7 736 447 1 0 1
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4. The fusion of X63 with SLE and MG PBL,
Twelve fusions were performed with SLE PBL and 
ten with MG PBL, The results are presented in tables 5.4 
and 5.5. An estimate of the number of hybrids resulting 
from each fusion can be obtained from the observed 
proportion of plated wells which show growth:
m = - loge (1 - p) 
where m = mean number of hybrids per well, 
and p = proportion of wells showing growth 
(Galfre and Milstein 1981).
The number of hybrids produced by fusion 
expressed as a fraction of the number of lymphocytes used 
is known as the fusion frequency. This was calculated 
from the data. The mean fusion frequency of X63 with 
normal PBL was 8.4 x 10~6 (S.D. 1.1 x lO""6 ), with MG PBL 
4.8 x 10 6 (S.D. 4.5 x 10 ^), and with SLE PBL was 4.5 x 
10~6 (SD 2.8 x 10"6 ).
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H.S. 1.7 X 107 170 34 5
J.B. 2.0 X 107 192 108 28
D.T. 3.0 X 107 192 140 30
N.G. 1.3 X 107 130 32 12
E.A. 3.0 X 107 192 119 22
M.W. 1.2 X 107 120 10 1
C-S.* 3.8 X 107 192 85 22
C-S.* 3.4 X 107 192 87 18
C-S.* 3.0 X 107 192 104 24
S.Wo. 1.4 X 107 140 7 1
S.Wa. 2.0 X 107 192 102 46
E.C. 0.9 X 107 90 25 11
Totals 2.7 X 108 1994 853 220
* Repeat samples from the same patient
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J.R. 1.1 x 107 96 20 4
J.Ro. 2.5 x 107 192 26 5
R.H. 2.5 x 107 192 61 13
S.P. 1.6 x 107 160 10 5
Sh.* 10 x 107 480 408 153
Sh. * 10 x 107 480 421 211
M.P. 2.7 x 107 192 38 3
S.T. 1.5 x 107 150 10 0
J.A. 1.6 x 107 160 84 24
J.S. 3.5 x 107 192 174 41
Totals 3.7 x 108 2294 1252 459
* PBL obtained from leukapheresis packs.
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5. The fusion of X63 with EBV-transformed lymphocytes.
Two fusions were performed using X63 and 
EBV-transformed PBL/ and one fusion using X63 and EBV 
transformed tonsil B cells. The results are shown in 
table 5.6.
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1—PBL 1.0 x 106 96 59 51
2-PBL II II 64 52
3-Tonsil It It 66 61
The calculated fusion frequencies were 105 x 
10"6 and 92 x 10"6 , for EBV-PBL and 112 x 10~6 for 
EBV-tonsil cells.
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6 . Cloning and stability of hybrids.
Thirteen hybrids were selected for cloning, 
including two from MG patients, eight from SLE patients 
and three from normal subjects. Ten produced IgM, 2 
produced IgG and one produced IgA. All except the IgA 
producing hybrid were selected on the basis of an 
antibody specificity.
Hybrids were cloned directly from the 96 well 
trays. The percentage of seeded wells which gave rise to 
daughter clones (i.e. the cloning efficiency) varied 
between 4% and 22%, with a mean of 9.6%. The fastest 
growing immunoglobulin positive clone for each hybrid was 
immediately re-cloned. The cloning efficiencies improved 
to a mean of 28% (range 6.3% to 46%).
Immunoglobulin synthesis was not detected in 
any daughter clones for one of the hybrids. However, for 
the remaining 12 hybrids between 29% and 90% of the 
daughter clones (mean 65%) were found to be producing 
human immunoglobulin after the first cloning.
On recloning, between 90% and 100% of the 
daughter clones were found to be producing immunoglobulin 
for all hybrids except one. This hybrid yielded only 74% 
immunoglobulin secreting clones. After recloning a third 
time, 92% of the daughters from this hybrid were 
positive for immunoglobulin secretion.
All 12 cloned hybrids continued immunoglobulin 
secretion through 6-8 months of continuous culture.
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7. Chromosome content of hybrids.
Chromosome numbers of unfused X63 and four cloned 
hybrids are presented in table 5.7. The hybrids were 
randomly selected and include two from normal subjects 
(MR and R H ), one from an MG patient (JA) and one from an 
SLE patient (SW). Representative metaphase spreads are 
shown in fig 5.1.
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Table 5.7 Chromosome content of hybrid cells.








Fig. 5.1 Representative metaphase spreads of X63 and 
derived hybrids.
(a) Unfused X63, (b) Hybrid RHB6, (c) Hybrid JAE6. 
Chromosomes are stained with Hoechst 33258. Hybrid 
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8 . Heavy chain and light chain isotype distribution of 
secreted immunoglobulin.
All hybrids obtained from fusions of NSl and 
X63 with PBL from normals/ autoimmune patients and from 
fusions with EBV transformed cells/ were screened for 
production of human IgG/ IgA and IgM. The proportion of 
the classes detected in the different groups is presented 
in table 5.8.
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Table 5.8 Distribution of immunoglobulin class secreted 
by mouse-human hybrids.
Fusion partners:




NSl-normal PBL 16 0 84 25
X63-normal PBL 7 2 91 101
X63-SLE PBL 19 10 71 220
X63-MG PBL 18 5 77 459
X63-EBV PBL 12 3 85 96
X63-EBV tonsil 11 8 81 61
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Supernatants of immunoglobulin secreting 
hybrids cultured for periods over two months were 
randomly selected and screened for kappa and lambda light 
chains. The results are presented in table 5.9.
Of 12 cloned hybrids cultured for periods of 
at least six months/ 10 were found to produce lambda 
chains and 2 to produce kappa chains.
The kappa:lambda ratio was tested for
2
association with fusion partner (tonsil vs PBL) by X .
2
There was found to be evidence of an association (X = 
4.856, d.f.= 1/ p< 0.05).
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Table 5.9 Light chain isotype frequencies of 
immunoglobulins secreted by hybrids.
Fusion partners:




X63-PBL 32 68 43
X63-EBV PBL 27 73 96
X63-EBV tonsil 46 54 61
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8 . Quantity of immunoglobulin secreted by hybrids.
Standard curves for the CELIA for human IgG,
IgM/ IgA and mouse IgG (whole molecule) are shown in 
figs. 5.2 - 5.6. Each point represents the mean of 
triplicate determinations; the standard deviations were 
within + 2.5%. The assays were specific and linear for 
each class of immunoglobulin over a range of 
approximately 10 ng ml ^ to 100 ng ml
The effect of mouse immunoglobulin on the 
assays for human immunoglobulin was investigated using 
dilutions of mouse serum. No inhibition was seen even at 
immunoglobulin concentrations of 100 yg ml ^ (assuming 
IgG to be 11.7 mg ml ^, IgM to be 1.0 mg ml  ^and IgA to
be 0.26 mg ml Hudson and Hay 1980).
Culture supernatants were collected as cells 
needed feeding. Pooled samples from 11 cloned and 24 
uncloned hybrids were assayed for human immunoglobulin 
concentration. This was found to vary between 1 yg ml ^
and 12 yg ml ^ for the different lines. There was no
apparent difference in the quantity secreted between 
hybrids secreting different classes of immunoglobulin. No 
mouse immunoglobulin was detected in any of these 
supernatants^ m  orn £.L\SA sensitive. \o lO m j  cr^ of <^ ©vaS£ XciQ.
O'
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10. Growth characteristics of Hybrids.
Culture flasks were seeded with unfused X63 or 
hybrid cell lines JSC8/ RHB6 and MRBl at a concentration 
of approximately 50,000 ml Small aliquots were removed 
at 24 h intervals and viable cells counted. The results 
are plotted in fig 5.7.










Time in culture (days).
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Discussion
The first critical step in the production of 
monoclonal antibodies is the generation of hybridomas 
from the two fusion partners with the highest possible 
efficiency. Reported fusion procedures vary enormously 
between laboratories. The technique used in this study 
was loosely based on the work of Fazekas de St. Groth and 
Scheidegger (1980)/ who attempted to optimise the fusion 
technique for rodent MCA production. In this study/ the 
HMy2 line was clearly inferior in generating hybrids to 
either the NSl or X63 mouse myelomas. Half the fusions 
failed to produce any hybrids and the overall fusion
-7
frequency was only 1.6 x 10 . This was significantly
— 6lower than NSl (1.7 x 10 ) which in turn was 
significantly lower than X63 (8.2 x 10 , Student's 
t-test p< 0.01 for both comparisons). HMy2 has now been 
sucessfully fused with lymphocytes from peripheral blood 
and lymph nodes as well as chronic leukaemic lymphocytes 
(Edwards ejt a_l. 1982/ Sikora £t a_l. 1982/ Abrams et a l .
1983). Reported fusion frequencies are between 10 and
— 8  —710 / with 10 being the usual.
Although depleting the T-lymphocytes before 
fusion resulted in no improvement/ it is possible that 
the fusion frequency of HMy2 could be increased by 
manipulating the variables involved in the fusion 
procedure. This was not attempted as the results with the 
murine lines were encouraging enough to merit pursuing.
The fusion frequency of X63 with normal PBL
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approached that commonly achieved with mouse-mouse 
fusions/ but was both lower and more variable with PBL 
from autoimmune patients. This is perhaps not surprising 
as the normal group were a small group of laboratory 
workers all in their mid-twenties. The autoimmune group 
were considerably more heterogenous in age (mid twenties 
to seventies) and general state of health. In addition 
there were variable delays between taking blood samples 
and fusing the isolated lymphocytes.
Fusion frequencies of X63 with EBV transformed 
PBL or tonsil cells were remarkably high. Table 5.10 
shows a comparison of the fusion frequencies for human 
and mouse cell lines with human lymphocytes as reported 
by the authors/ or where authors have supplied enough 
information to enable fusion frequencies to be 
calculated.
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X63 EBV- 92-112 (Present study)
(mouse) B-cells
X63 EBV- 20.0 Kozbor et al.
(mouse) B cell line (1982a)
KR-4 EBV- 11.2 Kozbor et al.
(human) B cell line (1982b)
LTR 228 PWM stim. 10.0 Larrick et al.
(human) PBL (1983)
X63 normal 8.4 (Present study)
(mouse) PBL
UC 729-6 CLL 3-10 Glassy et al.
(human) lymphocytes (1983)
NSl PBL (normal* 6.1 Cote et al.
(mouse) renal cancer] (1982)
NSl CCL 5.1 Foon et al.
(mouse) lymphocytes (1983)
X63 SLE and MG 4.7 (Present study)
(mouse) PBL
KR-4 Immune 3.6 Kozbor et al.
(human) PBL (1982b)
GM 1500 PBL 2.5 Eisenbarth et al.
(human) (diabetics) (1982)
HF2 CCL 2.2 Foon et al.
(human) lymphocytes (1983)
GM 0767.3 PWM stim. 2.2 Chiorazzi et al.
(human) tonsil (1982)
GM 1500 Immune 1.8 Croce et al.
(human) PBL (1980)
GM 4672 PWM stim. 1.7 Shoenfeld et al.
(human) SLE PBL (1982)
NSl normal 1.7 (Present study)
(mouse) PBL
UC 729-6 CLL 1.4 Foon et al.
(human) lymphocytes (1983)
U-266 CLL 1.0 Foon et al.
(human) lymphocytes (1983
HMy2 CLL 0.5 Foon et al.
(human) lymphocytes (1983)
UC 729-6 normal 0.5 Glassy et al.
(human) PBL (1983)
KR-4 normal 0.4 Kozbor and Roder
(human) PBL (1983)
TM-H2 normal 0 .1-0.7 Sullivan et al.
(human) PBL (1982)
HMy2 PBL (normal+ 0.3 Cote et al.
(human) renal cancer) (1982)
HMy2 normal 0.2 (Present study)
(human) PBL
HMy2 normal 0.1 Edwards et al.
(human) PBL (1982)
SK0-007 PBL (normal* 0.1 Cote et al.
(human) renal cancer) (1982)
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A number of conclusions can be drawn. For a 
particular cell line the fusion frequency is greater if 
the lymphocyte partner is EBV transformed (Kozbor 1982a/ 
1982b/ Kozbor and Roder 1983)/ of CLL origin (Glassy £t 
a l . 1983/) or PWM stimulated (Shoenfeld et^  al^ . 1982/ 
Larrick £t al. 1983) rather than normal PBL. The fusion 
frequency achieved in this study with X63 and 
untransformed PBL compares favourably with the best two 
human cell lines KR-4 and LTR 228 even though they were 
fused with EBV transformed B cells and PWM stimulated PBL 
B cell blasts respectively. The performance of X63 looks 
even more impressive if one considers that probably only 
^ 1 0 %  of the fusion partners were B cells. When X63 cells 
are fused with EBV transformed B cells/ the fusion 
frequencies are by far the highest. HMy2 fuses poorly 
compared to both other human and mouse cell lines/ in 
this and other studies.
The fusion frequency of a particular cell line 
obviously needs to be considered with regard to the 
proportion of derived hybrids which secrete human 
immunoglobulin. Although X63 is an efficient fusion 
partner/ only 10%-30% of the hybrids were found to 
produce human immunoglobulin when the fusion partner was 
untransformed PBL. This presumably reflects the fusion of 
X63 with non-B cells in the population. When fused with 
transformed B cells only/ 81% - 92% of the hybrids were 
found to secrete human immunoglobulin.
Comparative data on the percentage of
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immunoglobulin secreting hybrids from human cell-lines 
are shown in table 5.11. As well as fusing with 
relatively high efficiency/ 96% of hybrids derived from 
KR-4 fused with a B cell line secreted immunoglobulin 
derived from the latter. No data are available from 
fusion of this line with PBL. Similarly/ almost half the 
hybrids obtained from the human line LTR 228 produced 
immunoglobulin derived from the B cell blast fusion 
partners. HMy2 and SKO-007 generate a fairly high 
percentage of immunoglobulin-secreting hybrids but their 
fusion frequencies are both very low.
Table 5.11 New immunoglobulin secretion in hybrids 
derived from human cell partners and X63.
Cell line % hybrids secreting 
new Ig.
Ref.
KR-4 (i ) 96% Kozbor et al.(1982b)
X63(i) 81%-92% Present study
HMy2 65%-67% Foon ejt al. (1983) 
Cote et: al. (1982)
LTR 228 <50% Larrick e_t al. (1983)
SK0-007 47% Cote et al.(1982)
UC729-6 30%-60% Glassy et a l .(1983) 
Foon et a l .(1983)
X63(ii) 35% Kozbor et^  a l . (1982a)
X63(iii) 22% Present study
HF2 24% Foon et^  a l . (1983)
U—266 1% Foon et al.(1983)
(i) Fused with EBV-transformed B cells.
(ii) Fused with B cell line.
(iii) Fused with normal and autoimmune PBL.
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One major criticism of human-mouse hybrids has 
been that they are unstable. In this study/ long term 
hybrid instability was not a problem. Of thirteen hybrids 
selected for intensive study/ twelve were successfully 
cloned and continued to secrete immunoglobulin over at 
least a six month period of observation. There is a 
general feeling that such heterohybrids are 
unsatisfactory for producing human MCA as they 
preferentially lose human chromosomes and thus the 
ability to produce human immunoglobulin. It is not 
immediately apparent why stability was not a problem with 
the hybrids studied here; it may be a property of the X63 
line/ the autoimmune origin of the lymphocytes or some 
technical factor in the propogation of the hybrids. There 
is no reason to suspect that PBL from autoimmune patients 
are especially likely to confer stability in hybrids/ but 
this can only be established by fusing X63 to PBL of
other origins. Any peculiarities of the X63 line which
£
enable it to produce stable hybrids need be established 
by comparative studies. Kozbor (1982a) found hybrids 
generated from this myeloma and an B cell line to be 
stable for periods of >6 months and that hybrids retained 
a mean of 24 human chromosomes. Most hybrids examined in 
the present study contained many more chromosomes than 
the X63 line/ but it was not established how many were of 
human origin.
There are very many technical variables which 
may contribute to the stabilty of the hybrids/ such as
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type of feeder layer/ serum factors/ culture conditions 
etc* Although it seems unlikely that these are of 
significance/ it is of interest that Astaldi e_t a l .
(1980) found that human endothelial cell culture 
supernatant was able to increase the stability of 
mouse-human heterohybrids derived from the mouse myeloma 
SP2/0.
Perhaps the most important reason for the 
present success was the cloning of hybrids directly from 
the post-fusion trays as early as possible/ and the 
re-cloning until >90% of sub-clones produced 
immunoglobulin. Cote et^  al. (1983) found that 38% of 
uncloned hybrids from NSl lost immunoglobulin production 
in 2 to 3 months after fusion. This rose to 42% after 4 
months. Butler e^ t <al. (1983) found that when antigen 
specific clones derived from PBL and the mouse myeloma 
SPl were identified at 3 weeks and maintained without 
cloning/ production invariably ceased in the following 6 
weeks. Stable hybrids could be rescued by cloning at 3 
weeks however. Where mouse myelomas have been employed 
for generating stable immunoglobulin secreting 
human-mouse hybrids/ early/ aggressive cloning seems a 
common denominator (Nowinski ejt al. 1980/ Schlom et: al. 
1980/ Butler £t al. 1983).
The main and often quoted reason for developing 
a human myeloma hybrid partner for human MCA production 
is that human-human hybrids are stable with respect to 
chromosome loss ( Weiss et al.1967/ Croce et al.1974)/
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whereas mouse-human hybrids are are unstable (Croce et^  
a l . 1974/ 1980). Both these statements need some 
qualification. Many people are familiar with the 
production of mouse-human hybrids which segregate human 
chromosomes. These fusions have been utilised with great 
success in the area of somatic cell genetics for the 
mapping of human chromosomes. Heterohybrids are scored 
for the presence or absence of a human gene product and 
the presence or absence of each of the human chromosomes. 
Concordance between these is taken as evidence for the 
assignment of a marker to a particular chromosome 
(Goodfellow and Solomon 1982). It has been known for a 
long time that in such mouse-human somatic hybrids 
(usually fibroblasts)/ human chromosomes are 
preferentially eliminated (Weiss and Green 1967/ Matsuya 
and Green 1969/ Nabholz et a l . 1969). However/ 
preferential loss of human chromosomes is not a universal 
feature of mouse-human heterohybrids. Hybrids have been 
produced in which mouse chromosomes are preferentially 
lost (Jami and Grandchamp 1971/ Minna and Coon 1974/ 
Ringertz and Savage 1976). Such reverse chromosome 
segregation can also be induced by pre-treating the mouse 
cells with BrdU or radiation before fusion (Pontecorvo 
1971). Hybrids between human diploid fibroblasts and 
mouse RAG cells randomly lose chromosomes from both 
species (Chen 1979).
In mouse-human fibroblast hybrids human 
chromosome loss is not random. Chromosomes 1, 11/ and 12
-134-
are preferentially retained/ while others e.g. 9, are 
lost (Croce ej: al. 1973/ Norum and Migeon 1974/ Ruddle 
and Creagan 1975). When Croce et al. (1980) examined the 
retention of chromosomes in hybrids derived from the 
mouse myeloma cell lines P3X63.Ag8 and P326Bu4 with human 
lymphocytes/ they found human chromosomes to be lost/ but 
in a different pattern to the fibroblasts. Chromosomes 
14/ 22/ and 5 were retained in more than 50% of 
independent hybrids with chromosome 14 being retained in 
100%. Chromosomes 1 and 2 were found in less than 10% of 
hybrids. This is of some significance as human 
immunoglobulin heavy chain genes have been assigned to 
chromosome 14 (Croce e_t al. 1979/ Hobart et^  al. 1981)/ 
lambda light chain genes to 22 and kappa light chain 
genes to chromosome 2 (Erikson ejt a l . 1981). Thus if this 
is generally true of mouse myelomas one would expect 
hybrids producing lambda light chain immunoglobulin to be 
much more stable than hybrids producing kappa chain 
immunoglobulin. There was no suggestion from the present 
study that kappa chain producing hybrids were more 
unstable than lambda producers. Whereas there does seem 
to be a preference in the production of lambda secreting 
hybrids/ the twice cloned hybrids cultured for over 6 
months included two kappa producers. The stable hybrids 
produced from this myeloma by Kozbor (1982a) were kappa 
secretors/ so the production of MCA with kappa isotype is 
not precluded. The one hybrid which lost immunoglobulin 
production was initially producing IgM(lambda).
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If the problem of chromosome instability in 
mouse-human hybrids is not as bad as it has seemed/ there 
is accummulating evidence that it is more of a problem 
with human-human hybrids than originally envisaged. While 
some hybrids derived from some human lines have been 
reported to retain most of the parental chromosomes (KR-4 
Kozbor et: a_l. 1982/ UC729-6 Glassy ejt al^ . 1983/ LTR228 
Larrick et al.1983)/ there have also been reports of 
chromosome loss. The modal chromosome numbers in most 
hybrids derived from HMy2 are only 17 to 27 more than the 
parent myeloma (Edwards ejt a_l. 1982). Similarly Olsson et 
a l . (1983) report a rapid loss of chromosomes from 
hybrids of both RH-L4 and SK0-007. During 40 days after 
fusion/ the chromosome content of most hybrids fell from 
near tetraploid to between diploid and triploid. Many 
hybrids lost immunoglobulin production during this 
period. Cote et^  al.- (1983) found the loss of production 
of immunoglobulin by uncloned hybrids from the human 
lines HMy2 and SKO-007 to be comparable to immunoglobulin 
loss in hybrids derived from murine NSl. Foon ejt a l . / 
examining hybrids from the four human lines U-226/ HMy2/ 
HF2 and UC729-6/ found that the majority of hybrids lost 
immunoglobulin production at the first cloning stage. The 
authors suggest that this may have been due to switching 
off of gene function/ or loss of secretion rather than 
production. In the absence of any karyotypic analysis 
however/ it cannot be ruled out that chromosome loss may 
have been a factor.
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The isotype distribution of MCA derived from 
human lymphocytes has not been systematically researched. 
A predominance of hybrids secreting human immunoglobulin 
of the IgM class has been reported elsewhere for fusions 
with PBL (Glassy et: a^. 1983/ Chiorrazzi et: a_l. 1982) and 
with fusions of EBV transformed PBL (Kozbor and Roder 
1983). This presumably reflects the predominance of 
circulating B cells which are surface IgM positive 
(Pernis ejt aJ. 1971/ Froland and Natwig 1972/ Preud*Homme 
and Seligman 1972). Although IgG producing cells 
predominate in tonsil B cells/ mainly IgM producers are 
selected for following transformation by EBV (Yoshie et^  
a l . 1980). The kappa:lambda ratio of immunoglobulins 
produced by hybrids derived from human lymphocytes has 
not been well documented. It was surprising to find the 
kappa:lambda ratio of hybrids in this study to be*Sl:2.5 
(PBL derived) and 1:1 (tonsil derived). The ratio of 
kappa:lambda bearing B cells circulating in the 
peripheral blood has been reported to be«J?2:l (Seigmann 
ejt al^ . 1973). More carefully controlled studies have 
shown this to be ^ 51:1 (Vossen and Hijmans 1975). In 
cloned EBV-transformed tonsil cells Yoshie ejt al^ . (1980) 
found the ratio of kappa:lambda secreting clones to be 
2:1. Although the light chain ratios of 
immunoglobulin-secreting hybrids derived from PBL and 
tonsil were significantly different/ there would seem a 
lambda bias from the expected ratio in each case. The 
reason for this is not clear.
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The quantity of immunoglobulin secreted by 
X63-human hybrids is comparable to that reported for 
other fusion partners. Human cell lines typically 
generate hybrids which secrete between 0.1 and 10 yg ml * 
(Kozbor and Roder 1983/ Foon ej: al^ . 1983). Cote elb a l . 
found 70% - 75% of all hybrids generated with NSl or the 
two human lines HMy2 and SKO-007 to produce between 1 and 
10 yg ml-*/ with the remaining hybrids secreting up to 
100 yg ml-*. No mouse immunoglobulin was detected in 
hybrids generated from X63 and thus one can assume that 
all secreted immunoglobulin was derived from the 
lymphocyte fusion partner. This is not the case for most 
of the human cell lines. When both fusion partners 
produce immunoglobulin of their own the resulting hybrids 
continue to synthesise both immunoglobulins. Hybrid 
immunoglobulin molecules can thus be secreted/ 
effectively diluting the desired antibody and making 
isolation and idiotypic studies a problem. Even when the 
parent cell line only synthesises trivial amounts of 
immunoglobulin/ the resulting hybrids produce much higher 
quantities (Kozbor et^  a_1.1982). HF2 is the only human 
cell line which produces no immunoglobulin of its own.
In conclusion/ X63 was found to be superior to 
either the mouse myeloma NSl or the human lymphoblastoid 
line HMy2 in generating immunoglobulin-secreting hybrids. 
Many of the useful characteristics of the X63 line were 
found to be transferrable from the mouse-mouse fusions to 
the fusion with human PBL. The line fused with high
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efficiency and hybrids were robust in culture/ cloned 
easily and were recovered without difficulty from storage 
in liquid nitrogen. Stable hybrids were formed which 
secreted useful quantities of human IgM/ IgG, and IgA of 
both lambda and kappa isotypes. The X63 myeloma produces 
no immunoglobulin of its own and no murine immunoglobulin 
could be detected in the supernatants of human 
immunoglobulin-secreting hybrids. In comparison to human 
cell line fusion partners/ only LTR 228 and KR-4 generate 
human immunoglobulin secretors with an efficiency which 
approaches that of X63/ but both have the disadvantage of 
producing their own immunoglobulin. The only human 
non-producing cell line HF2 generates 
immunoglobulin-secreting hybrids at a far lower 
efficiency than X63. If the stability of the 
heterohybrids produced in the present study can be 
repeated in other situations/ the X63 line would seem to 
be by far the most suitable line currently available for 
the production of human MCA.
Chapter Six, The production of human autoantibodies by
human-mouse hybrids,
Results,
1. The RIA for antibodies to AChR
2. Failure to detect MCA to AChR
3. ELISAs for antibodies to nuclear and 
cytoplasmic antigens and rheumatoid factor
4. Characterisation of patients* sera by 
indirect immunofluorescence
5. The detection of MCA to nuclear 
and cytoplasmic antigens by ELISA
6. The detection of MCA by indirect 
immunofluorescence
7. The characterisation of MCA:
(i) Drug disarrangement of cytoskeletal 
structures














1. The RIA for antibodies to AChR.
Details of the RIA for anti-AChR antibodies 
have been published (Carter et aJ. 1981). This assay is 
used routinely in this department as a diagnostic aid for 
MG. The range of anti-AChR antibodies in normal human 
sera is 0-1 x 10 ^  mol 1 ^of a-bungarotoxin binding 
sites. The titres of antibodies usually found in MG sera 
are in the range 0-1500 x 10 ^  mol 1 ^ a-bungarotoxin 
binding sites. The antibody titres in the sera of the 
patients used in this study are presented in table 6.1.
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2. Failure to detect MCA to AChR.
459 human immunoglobulin-secreting hybrids made 
from MG patients were screened by RIA for anti-AChR 
activity. They were derived from 10 fusions using PBL 
from 9 different patients. 353 supernatants contained 
IgM/ 23 contained IgA and 83 contained IgG. No antibody 
activity to AChR was detected in any of the supernatants.
3. ELISA for antibodies to nuclear and cytoplasmic 
antigens and rheumatoid factor.
These assays have been the subject of previous 
studies establishing their sensitivity and specificity 
(Maddison et a_l/ in press/ Brennand 1983). The 
specificities of the ELISAs were confirmed using known 
standard monospecific sera. Typical binding curves are 
shown in fig 6.1. Positive and normal sera controls were 
included in all assays. The ELISAs confirmed the 
individual serological data obtained by double diffusion 
for antibodies to soluble ribonucleoprotein antigens/ and 
RIA for anti-DNA antibodies. (Table 6.2). All patients 
gave clear positive ELISA results at serum dilutions of 
at least 1:10/000.
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Fig. 6.1 Typical binding curves of ELISAs using standard 
sera.
Points shown are means of triplicates. Variation between 
replicates was less than 0.1 O.D. units. In each case, 
the positive serum is an accepted reference standard 
containing precipitating antibodies against the antigen 




Absorbance at 280 nm
to 01
I/)



































W i 1 1 iams
NHS
o




Absorbance at 280 nm
o O O M M






Table 6.2. Antibody specificities present in SLE 
patients 1 sera.
Patient Diagnosis Precipitins Anti-DNA
HS SLE Ro & La +
JB SLE Ro & La +




EA SS Ro -
MW MCTD nRNP -
CS SLE/SS Ro -
S Wo MCTD nRNP +
SWa MCTD nRNP +
EC SLE Ro & La +
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4.Characterisation of patients1 sera by indirect 
immunofluorescence.
The sera of the patients used in this study 
were screened by indirect immunofluorescence against 
HEp-2 cells and normal human fibroblasts. Titres were 
obtained by serial dilution of the serum samples and were 
defined as the reciprocal of the highest dilution of 
serum giving visible fluorescence under a UV microscope. 
Titres were obtained using both an anti-polyvalent human 
immunoglobulin-FITC conjugated second antibody/ and an 
IgM specific conjugate. Under the conditions described in 
the methods section/ no staining was observed in a series 
of 10 normal sera diluted 1:8 or greater. Titres of 8 or 
greater were accordingly considered positive. There was 
little difference when either HEp-2 cells or fibroblasts 
were used as a substrates. Results for both polyvalent 
and IgM serum antibodies against human fibroblasts are 
presented in table 6.3. All SLE patients gave positive 
results as did one MG patient (JA). IgM autoantibodies 
were either absent or present at very low titre.
-149-
Table 6.3. Characterisation of sera by indirect 
immunofluorescence.
Patient Cytoplasmic staining
















DT hazy 8 * fine
speckled
1024 32
NG hazy 32 8 fine
speckled
32 8



























5. The detection of MCA to nuclear and cytoplasmic 
antigens by ELISA,
220 human immunoglobulin-secreting hybrids from 
SLE patients were screened for antibody activity against 
Ro/ La/ nRNP/ Sm and IgG. They were derived from 12 
fusions using PBL from 10 different patients. 156 of the 
supernatants screened contained IgM/ 22 contained IgA and 
42 contained IgG. No antibodies were found that reacted 
specifically with any of these antigens. Fourteen MCA 
were found that apparently reacted with more than one of 
these antigens.
When these 14 supernatants were screened 
against ELISA cuvettes coated without antigen but with 
casein blocking protein/ 10 demonstrated binding. This 
binding was unaffected when BSA was substituted for 
casein. The four MCA which were not 'false positives' 
were all comparatively weak by ELISA and needed extended 
substrate incubation times ( ^ 2  hours) to be 
demonstrated. Their reactivities were to both Ro and La 
(CSD4 and NGBl)/ to La and nRNP (SWG10) or to L a / Ro and 
nRNP (HSE7).
6. The detection of MCA to nuclear and cytoplasmic 
antigens by indirect immunofluorescence.
The 14 supernatants showing reactivity in the
* SEE
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ELISAs were screened by indirect immunofluorescence 
against fixed human fibroblasts and HEp-2 cells. In 
addition/ the 124 human immunoglobulin positive wells 
from four SLE fusions (CS/ SWo/ SWa and EC)/ together 
with 65 immunoglobulin positive wells from two MG fusions 
(JA and JS)/ 54 immunoglobulin positive wells from two 
healthy subject fusions (RH and MR) and 128 
immunoglobulin positive wells from fusions with EBV 
transformed lymphocytes were similarly screened. Results 
were similar using either fibroblasts or HEp-2 cells as 
targets. The results are shown in table 6.4.
*
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Table 6.4 Detection of MCA by indirect immunofluorescence 
against human fibroblasts.
Hybrids No screened No +ve IIF Pattern
SLE PBL(false 
+ve ELISA)
10 10 Cytoplasmic filaments (10)
SLE PBL 
(+ve ELISA)
4 2 Even cytoplasm (2)
SLE PBL 
(-ve ELISA)
124 2 Cytoplasmic filaments (2)
MG PBL 65 3 Cytoplasmic filaments (2) 
" and nucleus (1)
Normal PBL 54 3 Cytoplasmic filaments (3)
EBV-PBL 80 5 Cytoplasmic filaments (4) 
Even cytoplasm (1)
EBV-tonsil 48 3 Cytoplasmic filaments (2) 
Even cytoplasm (1)
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Fluorescent staining was seen in hybrids from 
all sources. Four hybrid supernatants (CSD4, and HSE7 
from SLE patients/ and 1 each from the EBV-tonsil and 
EBV-PBL fusions) showed an even cytoplasmic/membrane 
staining pattern (fig 6.2). Twenty-four others showed a 
filamentous cytoplasmic staining pattern (fig 6.3). In 
addition to a cytoplasmic filament staining pattern/ one 
hybrid supernatant (JAE6) stained the entire nucleus (fig 
6.4).
All 10 of the MCA giving false positive 
reactions by ELISA showed clear filamentous staining of 
fibroblasts.
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Fig. 6.2 Even cytoplasmic/membrane immunofluorescent 
staining pattern shown by four MCA (CSD4, HSE7/ E2A7, 
T1F7) against acetone-fixed human fibroblasts.
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Fig. 6.3 Cytoplasmic filament staining pattern shown by 
twenty-three MCA against acetone fixed human fibroblasts.
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Fig. 6,4 (a) Cytoplasmic filament and nuclear staining 
pattern shown by MCA JAE6 against acetone-fixed human 
fibroblasts. Compare with (b) nuclear staining pattern 
shown by JA serum diluted 1:20 also against human 
fibroblasts.
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7. The characterisation of MCA:
(i) Drug disarrangement of cytoskeletal structures.
Eleven hybrids showing positive reactions 
against fixed human cells by indirect immunofluorescence 
were twice cloned and characterised further. Staining 
patterns against fixed fibroblasts were compared with 
fibroblasts pre-treated with either Colcemid/ vinblastine 
or cytochalasin B. Sixteen uncloned cell supernatants 
were similarly screened.
Seven of the cloned MCA showing cytoplasmic 
filament staining patterns on HEp-2 and human fibroblasts 
(CSHll/ SWF2/ SWD10/ JAA10, SWH10, MRD12, RHB6) showed a 
pattern of collapsed filaments around the nucleus when 
the cells had been pre-treated with either Colcemid or 
vinblastine (fig 6.5). This is typical of vimentin-type 
intermediate filaments. Pre-treatment of cells with 
cytochalasin B had no effect on the staining pattern.
This was seen with 14 filament-staining supernatants from 
uncloned hybrids.
The 2 cloned MCA (CSD4 and HSE7) and 2 uncloned 
supernatants showing even cytoplasmic staining 
demonstrated no change following any drug treatment.
One cloned MCA (CSDl) giving a cytoplasmic 
filament staining pattern, showed a collapsed perinuclear 
filament pattern following either Colcemid or vinblastine 
treatment, but with parallel bundles remaining stained
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throughout the cytoplasm. Although treatment with 
cytochalasin B alone did not make any obvious difference/ 
when fibroblasts were treated with both Colcemid and 
cytochalasin B/ the perinuclear filaments remained 
visible but no parallel bundles could be seen (fig 6.6). 
This is consistent with both the intermediate filaments 
and microfilaments being bound by the MCA.
The 1 cloned MCA showing nuclear and 
cytoplasmic filament staining (JAE6) demonstrated no 
change after treatment of the cells with cytochalasin B. 
The cytoplasmic filaments collapsed after treatment with 
either Colcemid or vinblastine/ but the nuclear staining 
remained unaltered (not shown).
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Fig. 6.5 The effect of Colcemid treatment on the staining 
patterns seen with MCA to cytoplasmic filaments, (a) 
Staining seen with untreated fibroblasts, (b) Following 
treatment of fibroblasts with Colcemid/ the filaments are 





Effect of Colcemid on the staining pattern shown 
by one MCA/ CSDl. Following Colcemid treatment (b)/ 
collapsed filaments can be seen around the nucleus and 
also parallel bundles in the cytoplasm. The parallel 
bundles disappeared following treatment with 
cytochalasin B.
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(ii) Jto situ fractionation of cell substrates.
MCA staining patterns were observed after each 
step of the iri situ fractionation procedure described in 
chapter 4, i.e. detergent extraction/ DNase treatment and 
high salt extraction.
The 8 cloned MCA showing cytoplasmic filament 
reactivities showed very little change of staining after 
each of these steps (fig 6.7).
The 2 cloned MCA showing an even staining 
pattern showed a more filamentous pattern following 
treatment of the fibroblasts with NP-40/ but this was not 
altered following the subsequent DNase and high salt 
extractions (fig 6.8).
The 1 cloned MCA (JAE6) showing cytoplasmic and 
nuclear staining lost the nuclear staining following the 
DNase treatment. The cytoplasmic filament staining was 
resistant to all treatments (fig 6.9).
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Fig. 6.7 Staining pattern of cytoplasmic filament-reactive 
MCA (CSHll) against fibroblasts treated with detergent/ 
DNase and high salt extractions.
»
4
Fig. 6.8 Staining pattern of even 
cytoplasm/membrane-reactive MCA (HSE7) following 
extraction of fibroblasts with detergent/ DNase and
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Fig. 6.9 Effect of In situ fractionation on the staining 
pattern of JAE6.
(a) Filament and nucleus staining unaffected following 
detergent extraction.
(b) Nuclear staining abolished following DNase 
extraction.





The data on the monoclonal autoantibodies derived from 
all sources are summarised in table 6.5,
Table 6.5
(a) Summary table of monoclonal autoantibodies derived from SLE 
patients.
























(anti-Ro) NGBl IgM Ro+La cytoplasm/membrane
HS































(anti-nRNP) SWA 3 IgM negative IF
EC
(anti-Ro+La)ECD2 IgM negative IF
* Twice-cloned hybrids.
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(b) Summary table of monoclonal autoantibodies derived from MG 
patients.












JSC8 IgM N.D. IF
* Twice-cloned hybrids. 
N.D. Not done.
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(c) Summary table of monoclonal autoantibodies derived from 
normals.
Source Hybrid Ig class Elisa reactivity Specificity
Normal PBL MRD12* IgM N.D. IF
RHB6* IgM N.D. IF
EBV-PBL 1 E1D2 IgM N.D. IF
E1F6 IgM N.D. IF
E1G2 IgM N.D. IF
EBV-PBL 2 E2A7 IgM N.D. cytoplasm/membrane
E2E1 IgM N.D. IF
EBV-tonsil T1B6 IgM N.D. IF
T1F7 IgM N.D. cytoplasm/membrane
TlEll IgM N.D. IF
N.D. Not done.




A striking feature of these results is that 
while both the MG and SLE groups were selected on the 
basis of high titres of serum antibodies (extremely high 
titres of autoantibodies were found in some of the 
patients)/ of 679 immunoglobulin-secreting hybrids 
screened/ not one was detected with a specificity which 
was anticipated from the data on the patients' sera. This 
is in contrast to what is usually found in mouse-mouse 
fusions using spleen cells from an immunised animal/ when 
frequently a large percentage of hybrids secrete MCA 
specific for the immunogen. The early reports of success 
in human-human fusions showed a high percentage of 
hybrids to make antibody of desired specificity (Olsson 
and Kaplan 1980/ Croce ejt al. 1980).
One possibility to explain why no MCA of 
desired specificity were found is that the assays were 
not sensitive enough to detect them. The RIA for 
antibodies to AChR is dependent upon the integrity of a 
protein which may have been subject to considerable 
proteolysis. Muscle was obtained from legs amputated 
because of either vascular disorders or diabetic 
gangrene. It would seem likely that the leg muscles were 
probably subjected to varying periods of ischaemia with 
attendant partial autolysis. During the extraction steps 
considerable quantities of proteolytic enzymes were 
probably released and the enzyme inhibitors included in
-170-
the extraction buffers may not have completely protected 
the receptor. Thus there may have been receptor present 
with intact antigenic determinants/ but unable to bind 
labelled toxin. Conversely/ receptor may have been 
present which bound labelled toxin/ but had certain 
antigenic determinants destroyed by proteolysis. A 
polyvalent antiserum might be expected to show 
considerable reactivity in such a situation of partial 
degradation of receptor/ whereas the binding of a MCA 
would show an all or nothing binding. Carter e_t a l .
(1981) reported that most myasthenic sera were capable of 
precipitating only 46-86% of toxin-labelled AChR under 
conditions of excess serum. This may support the notion 
that much of the receptor is indeed degraded.
However/ the RIA was shown to be adequate/ at 
least for certain specificities of MCA/ by raising murine 
MCA against electric eel AChR and demonstrating that some 
of these could cross react with human AChR in such a RIA 
and give a clear positive result (data not shown).
Loss of certain antigenic determinants may have 
occurred during the purification of the ribonuclear 
proteins/ again by proteolysis or denaturation during 
acid elution from the affinity columns. However/ positive 
ELISA reactions could be demonstrated for some of the SLE 
patients' sera at dilutions as high as 1 : 100/000/ which 
suggests that the assays should have been sensitive 
enough to detect at least some MCA.
Human or rodent MCA may demonstrate "assay
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specificity". That is they may perform excellently in one 
assay but give mediocre or even negative results in 
another (Haaijman e_t al^ 1984). It was for this reason 
that indirect immunofluorescence was additionally used as 
a screen. Although certain antigenic determinants may 
have been lost during acetone fixation/ extensive 
proteolysis should have been avoided. That no expected 
specificities of MCA were demonstrated by either type of 
assay indicates that the failings were not due to "assay 
specificiy".
Another possible explanation of why no expected 
MCA specificities were made concerns the source of the 
lymphocyte fusion partner. The peripheral circulation may 
be a poor source of lymphocytes of relevant specifities 
as compared to either spleen or lymph node tissue. The 
immunoglobulin class and subclass distribution of 
immunoglobulin-positive,circulating lymphocytes does not 
reflect the relative concentrations of serum 
immunoglobulins (McConnell 1975). IgM positive cells 
account for about 82% of immunoglobulin positive B cells 
but only 8% of serum immunoglobulin. Conversely/ IgGl and 
IgA positive cells form less than 2% of circulating B 
cells but account for 72% of the total serum 
immunoglobulin. It is possible that predominant antigen 
binding specificities of serum immunoglobulins may be 
similarly poorly represented in the circulating blood 
lymphocyte population.
In this context it should be noted that the
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predominant class of immunoglobulins made by the hybrids 
was IgM, yet very little of the serum autoantibodies were 
found to be of this class in the SLE patients' sera, and 
IgG is by far the most prevalent class in which anti-AChR 
antibodies are found in MG sera (Lefvert 1981).
Although little work has been done to compare 
lymphocytes from different sources/ Olsson et^  al_. (1983) 
compared the fusion of spleen cells and PBL of mice 
immunised with SRBC. Fusions with PBL yielded far fewer 
growing hybrids and far fewer immunoglobulin-secreting 
hybrids. However/ when the percentage of 
immunoglobulin-secreting hybrids which make anti-SRBC 
antibodies is compared there is very little difference 
between the two sources of lymphocytes (table 6.6).
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Table 6.6 Comparison of lymphocyte source in the 







% of Ig +ve secreting 
anti-SRBC antibody
SRBC 64% 50% 16%
PBL 5% 2.5% 20%
-174-
Extrapolating to the human situation/ one might 
expect that where antigens have either been administered
or the subject is undergoing an immune response to an
infectious agent/ fusions with PBL should yield antibody 
secretors with reasonable frequency. Indeed many of the 
successes in producing human MCA by fusion with PBL have 
followed immunisation or infection with e.g. tetanus 
toxoid (Butler et^  al^ . 1983/ Larrick et^  al^ . 1983)/ Keyhole
limpet haemocyanin (Lane et^  a_l. 1982)/
2/4-dinitrochlorobenzene (Olsson and Kaplan 1980)/ Rhesus 
D positive cells (Bron e_t al. 1984) and measles virus 
(Croce et al. 1980).
Haskard and Archer (1984) studied another 
autoimmune disease/ rheumatoid arthritis/ and found only 
one hybrid from 530 human-human hybrids to make 
rheumatoid factor. It seems probable that during chronic 
autoimmune responses/ as seen in the patients in this 
study and the RA patients of Haskard and Archer’s study/ 
the appropriate B cell specificities or B cells at the 
appropriate state of activation for fusion are not as 
well represented in the peripheral circulation as the 
cases outlined above. Although the ELISAs for
antibodies to La/ Ro/ Sm/ nRNP and IgG have been 
demonstrated to be both sensitive and specific/ no MCA 
from the SLE fusions were found which were specific for a 
single antigen. Four were found which reacted weakly with 
2 or 3 antigens. Ten were found which apparently reacted 
with the ELISA cuvettes/ even though the latter had been
-175-
blocked by either casein or BSA. Only one MCA (JAE6 from 
an MG patient) demonstrated a specific reactivity by
ELISA/ in this case anti-DNA.
It seems unlikely that the 4 MCA from SLE 
patients which reacted with 2 or 3 antigens by ELISA are
representative of circulating antibodies peculiar to SLE/
and certainly do not represent the specific ANA 
characteristic of this disease. Whereas these MCA clearly 
gave higher ELISA readings compared to irrelevant MCA of 
even 10 fold higher concentration/ both SLE and normal 
sera diluted 1:1000 (i.e. to levels of immunoglobulin 
comparable to the MCA in the supernatant) demonstrated 
equal or higher binding to the immobilised antigens. It 
seems doubtful that such weak binding is of significance. 
It may represent the binding of antibodies to minor 
impurities in the ribonuclear antigen preparations.
In this context it should be noted that only 
two of the four MCA showing Restricted* ELISA 
reactivities demonstrated binding to cells by 
immunofluorescence. The even staining patterns shown by 
these and two similar MCA from normals are not typical of 
patterns given by ANA positive sera. The antigen(s) 
involved are insensitive to cytoskeleton-disrupting 
drugs/ and are resistant to detergent/ DNase and salt 
extraction. Their location is thus more likely to be the 
cytoplasm than the membrane. Cote et: «al. (1983) described 
human anti-cytoplasmic MCA derived from both cancer 
patients and normals which gave a similar
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immunofluorescence pattern against cultured cells/ but 
the authors reported no attempt to further characterise 
the antigen(s) involved* While more work needs to be done 
on characterising the specificity of these MCA/ they do 
not seem to be related to overt disease*
The most suprising finding of this study was 
the high percentage of human MCA which bound to 
cytoskeletal structures. They were found in MCA derived 
from SLE PBL (9%)/ MG PBL (5%)/ normal PBL (6%)/ 
EBV-transformed PBL (5%) and EBV-transformed tonsil B 
cells (4%). The structures recognised form perinuclear 
coils after treatment with Colcemid or vinblastine/ but 
are not affected by cytochalasin B, and they are 
resistant to extraction by high salt/ DNase and 
detergent- The drug treatment and iri situ fractionation 
data are thus consistent with the cytoskeletal structures 
being intermediate filaments of the vimentin type 
(Virtanen/ 1984). As has been discussed in Chapter One/ 
intermediate filament antibodies have been frequently 
reported in human sera. Antibodies predominantly of the 
IgM class are found to be elevated during acute viral 
infections such as hepatitis/ chicken pox/ measles/ mumps 
and infectious mononucleosis (Toh et^  aJU 1979).
Similarly/ in 82% of sera from patients with acute 
malaria/ IgM antibodies to intermediate filaments could 
be demonstrated/ compared to only 8% of normal sera 
(Mortazavi-Milani et al. 1984a). Elevated 
anti-intermediate filament antibodies have been reported
-177-
in a number of autoimmune diseases; Angioimmunoblastic 
lymphadenopathy (Dellagi <et al. 1984)/ RA (Osung a l . 
1982)/ CREST and SLE (Senecal £t a_l. 1982/ Alcover et 
al,1984/ Kurki et al. 1983). Normal PBL can be induced to 
produce anti-vimentin intermediate filament antibodies in 
vitro by polyclonal activators such as EBV (Whitehouse et 
a l . 1974/ Mortazavi-Milani et al. 1982). In MCA 
production in mice/ Dales et^  al. (1983) found that after 
immunisation of Balb/c mice with vaccinia virus/ fusions 
preferentially yielded hybrids secreting antibodies with 
binding activity to intermediate filaments of mouse and 
human cells. Recently Haskard and Archer (1985) have 
reported that 10 of 425 human-human hybrids from RA 
patients produced anti-intermediate filament MCA.
The presence of antibodies to intermediate 
filaments has been taken to indicate the presence of a 
viral infection. This is partly because of the large 
number of viral infections described in which 
anti-intermediate filament antibodies have been found/ 
and also because a cross-reaction of measles virus 
phosphoprotein and herpes simplex virus protein with 
intermediate filaments has been described (Fujiyami ejt 
a l . 1983). The presence of anti-intermediate filament 
antibodies has been taken as evidence of a viral 
aetiology for SLE (Alcover ejt al_. 1984)/ and 
angioimmunoblastic lymphadenopathy (Dellagiet: al^ . 1984). 
Allison et: al. (1971)/ and Toh ejt al. (1979) suggested 
that viral antigens and cytoskeletal structures may
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facilitate autoimmunisation by stimulating helper or 
by-passing suppressor T cells.
An alternative explanation for the appearance 
of anti-intermediate filament antibodies is that they are 
produced not by antigenic stimulation/ but by polyclonal 
activation. This explains their appearance in situations 
where viruses are not implicated/ such as malaria and 
trypanosome infections (Mortazavi-Milani et: al^  1984)/ and 
in vitro responses of lymphocytes to polyclonal 
activators (Mortazavi-Milani et al 1982). The finding of 
this study that MCA to intermediate filaments can be 
produced with high frequency not only from autoimmune 
patients but also from healthy subjects supports this 
idea. If the high frequency of MCA with specificities for 
intermediate filaments reflects a similar proportion of 
circulating B cells with such specificities/ then it is 
not suprising that anti-intermediate filament antibodies 
appear in the serum in diverse situations which have in 
common a polyclonal activation component.
As no anti-intermediate filament antibodies 
were detected in the sera of the subjects in this study/ 
it seems probable that the population of B cells which 
were fused represented a precursor or possibly memory 
population. That the majority of hybrids secreted IgM is 
consistent with this idea. It could be argued that such a 
high proportion of anti-intermediate filament specific B 
cells reflects a history of viral infection. However/ the 
presence of such large numbers in normal subjects/ and
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the ease in which they can be elicited by polyclonal 
activators warns against attributing too great a 
significance to their appearance in certain diseases or 
taking their presence as indicative of a viral aetiology 
for any of the autoimmune diseases.
It is very suprising that such a large 
percentage of B cells are programmed to produce 
antibodies to intermediate filaments. It is possible that 
certain B cells are preferentially fused/ and these 
include a misleadingly high proportion of 
anti-intermediate filament reactive cells. However/ the 
widespread occurrence of serum antibodies with this 
specificity argues that the B cell repertoire is indeed 
biased to produce such antibodies. It may be that 
autoantibodies of this specificity may be involved in the 
normal physiological removal of tissue degredation 
products as suggested by Grabar (1983). Circulating 
levels of such autoantibodies would conceivably be 
controlled to such levels as necessary for this function. 
Thus anti-intermediate filament antibodies may be present 
in normal sera in their complexed form and hence not 
detected until such circumstances (e.g. polyclonal 
activation) that they are in excess over their antigen 
concentrations. If this is so there must be something 
peculiar to the removal of intermediate filaments that 
merits so much of the immune system's attention/ and why 
this should be so is not clear. Another problem with this 
explanation (and Grabar's theory in general) is that
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agammaglobulinaemia patients should be expected to show 
some symptoms resulting from inadequate clearance of 
intermediate filaments (and other tissue degradation 
products)/ and no such symptoms have been recognised.
The anti-intermediate filament MCA isolated in 
this study demonstrated some interesting cross-reactions. 
JAE6 from a myasthenic patient stained both intermediate 
filaments and the entire nucleus. The nuclear staining 
but not the intermediate filament staining was abolished 
by DNase treatment/ and by ELISA a very strong reaction 
was demonstrated to DNA/ but not RNA/ IgG or any 
nucleoproteins. Such a cross reaction has recently been 
recognised by Andre-Schwartz ejt a_l. (1984) The authors 
described 4 human monoclonal antibodies isolated from SLE 
patients which give very similar staining patterns and 
sensitivities to both cytoskeletal-disrupting drugs and 
DNase/ as does JAE6. By immunoblot tequniques they found 
the MCA to recognise a protein of Mr 54/000 consistent 
with the vimentin polypeptide.
One MCA/ CSDl/ from an SLE patient/ recognised • 
both Colcemid and cytochalasin B-sensitive cytoskeletal 
structures. This is consistent with the MCA recognising 
both intermediate filaments and microfilaments. The 
microfilaments were visibly stained after disruption of 
the intermediate filaments by Colcemid and displayed a 
highly characteristic pattern. Although the main protein 
of microfilaments is actin/ several other proteins are 
also present (Schliwa 1981/ Korn 1982). The exact protein
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recognised in the microfilaments by CSDl needs to be 
determined by immunoblotting. The demonstration of a 
cross reaction between intermediate filaments and 
microfilaments by a MCA has not to the author's knowledge 
been reported before.
The 10 MCA which bound to both blocked ELISA 
trays and intermediate filaments represents a 
cross-reaction only very recently recognised in the 
literature. Haskard ej: a_l. (1985) reported 5 of 383 
IgM-secreting hybrids derived from RA patients gave a 
similar 'false positive' reaction on blocked 'Falcon' 
ELISA trays. Of these/ 4 gave immunofluorescence patterns 
expected of anti-intermediate filament antibodies in that 
they stained filaments which collapse on treatment with 
Colcemid. This cross-reaction may occur through either 
common epitopes being present on the assay plates and 
intermediate filaments/ or through binding of MCA by 
non-idiotypic sites i.e. not conventional 
antibody-antigen combinations.
A feature of experiments with MCA in general 
has been the repeated demonstration of cross-reacting 
sites on molecules in which conventional serology has 
failed to detect homology (Lane and Koprowski/ 1982).
Many of these cross-reactions are between unrelated 
molecules. Thus Hannestad and Stollar (1978) reported a 
MCA which bound to both the Fc portion of IgG and 
chromatin/ Jacob et al . (1984) found a MCA which reacted 
to both DNA and a cell surface protein/ and Wood et al.
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(1982) found a MCA to a surface antigen of Trypanosoma 
cruzi which also reacted with neurons and cardiac muscle. 
In the literature of cross-reacting MCA/ 
anti-intermediate filament specificities are becoming 
pre-eminent. Dulbecco et: a_l. (1981) found 3 of 13 rodent 
monoclonal anti-Thy-1 antibodies (2 IgM and 1 IgG) to 
react with vimentin-type intermediate filaments. Blase et 
a l . (1982) reported a MCA-defined common determinant 
between tropomyosin and vimentin. Dales ej: a_l. (1983) 
found among many IgM/ anti-intermediate filament MCA 
derived from Balb/c mice immunised with vaccinia virus/ 1 
IgM MCA which also recognised the virally-coded 
haemagglutinin glycopeptide. Fujinami ejt a_l. (1983) 
described two rodent MCA; one which bound the 
phosphoprotein of measles virus and intermediate 
filaments/ and another which bound both a protein of 
herpes simplex virus and intermediate filaments. 
Andre-Schwartz cst al^ . (1984) found 4 IgM MCA from SLE 
patients which were selected as anti-DNA which also bound 
vimentin intermediate filaments. Rubin ejt al_. (1984) 
found 4 of 23 mouse monoclonal IgM anti-IgG antibodies 
which also bound to intermediate filaments. It seems very 
unlikely that a single cross-reacting epitope can explain 
all these observations. As these MCA recognise 
intermediate filaments and a single other antigen (DNA or 
IgG/ or plastic rather than all 3 for example)/ one would 
have to suppose that intermediate filaments carry a large 
number of epitopes with fortuitous cross-reactivities on
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unrelated molecules. A more reasonable explanation is 
that two distinct regions of the antibodies are involved 
in binding; the variable region to the antigen and either 
a part of the variable region or a completely distinct 
region of the immunoglobulin concerned with binding to 
intermediate filaments. The amino acid sequence of the 
immunoglobulin concerned with intermediate filament 
binding may be a fairly frequent event independent of 
antigen-driven/ clonal expansion. It is perhaps 
significant that the overwhelming majority of 
anti-intermediate filament antibodies are of the IgM 
class/ suggesting that perhaps the binding is dependent 
on a structural feature usually restricted to a 
proportion of this class of molecules.
In conclusion/ this study has found that MCA 
with autoantibody specificities are made with only very 
low frequency when PBL are fused from SLE and MG patients 
with extremely high titres of serum autoantibodies. 
Expansion of the PBL with EBV prior to fusion would allow 
many more immunoglobulin-secreting hybrids to be screened 
without increasing the absolute frequency of relevant 
clones. Solid lymph tissue from autoimmune patients may 
be a better source of lymphocytes with autoantibody 
specificities than the peripheral circulation. MCA with 
specificities for intermediate filaments were a common 
feature of hybrids produced from PBL and tonsil from 
normals and autoimmune patients. This is consistent with 
a large percentage of B cells being present in the normal 
circulation reactive with intermediate filaments and
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capable of secreting antibodies in the diverse situations 
reported. The finding here and elsewhere that very many 
of these anti-intermediate filament MCA show unexpected 
cross-reactivities with unrelated molecules/ and their 
class almost always being IgM/ suggests that the 
intermediate filament binding may not be a conventional 
antigen-antibody binding. This should warn against 
attaching to much significance to their appearance in 
viral or autoimmune diseases.
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Conclusions.
The first aim of this project was to evaluate
the performance of one human fusion partner/ HMy2# and
two mouse partners# NS1 and X63# in the production of
human MCA by the PEG-induced fusion method. Serious
problems were encountered with the human fusion partner.
Half the fusions performed with the HMy2 line failed to
produce any hybrids# and overall only one hybrid was
7
formed per 1.6 x 10 lymphocytes fused. This is 
approximately one thousand times less efficient than 
fusions involving rodent-rodent fusion partners. As only 
limited numbers of lymphocytes were available from 
autoimmune patients# such a low fusion frequency made it 
impractical to attempt making human MCA with this line. 
The HMy2 line also suffers from the disadvantage of 
secreting IgG# and thus hybrids formed from it are likely 
to secrete mixed molecules resulting in considerable 
dilution of the desired antibody. These two problems have 
been reported by other workers with this line and almost 
all other fusion partners. Despite considerable effort# 
no human fusion partner has been made which compares 
favourably in performance with rodent cell lines used for 
making rodent MCA.
Both murine fusion partners# NSl and X63 were 
found to fuse with human PBL with higher efficiency than 
did HMy2. All fusions with these lines yielded hybrids# 
and the fusion frequencies were approximately 15-50 times
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higher than achieved with HMy2. As the X63 line fused 
with the highest frequency and produces no immunoglobulin 
of its own/ this line was selected for intensive study.
As well as fusing efficiently/ the hybrids derived 
performed excellenty. Hybrids were made which supported 
the secretion of all major classes of human 
immunoglobulins of both kappa and lambda isotype. The 
hybrids cloned efficiently/ were robust in culture and 
were easily recovered from storage in liquid nitrogen. By 
cloning early and repeatedly until all daughter clones 
were positive for immunoglobulin secretion/ no problems 
of hybrid instability were encountered. For the majority 
of hybrids only two cloning steps were required to 
achieve stability.
The transformation of lymphocytes by EBV prior 
to fusion was found to be extremely advantageous. The 
fusion frequency was found to be even greater 
(approximately 1 x 10~4 ) and -85% of the hybrids 
secreted human immunoglobulin compared to 10-30% when 
untransformed lymphocytes were fused. This represents a 
50 fold increase in efficiency of generation of 
immunoglobulin-secreting hybrids. A population of 
dividing/ transformed B cells also permits repeat fusions 
to be made from a single sample/ and thus alows selection 
and expansion of cells making desired antibodies prior to 
fusion. The first problem which has plagued human MCA 
production/ i.e. the efficient establishment of human 
immunoglobulin-secreting cell lines has thus been
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over come . The method outlined above represents a major 
improvement over currently used techniques/ in terms of 
the number of immunoglobulin-secreting hybrids which can 
be made from small samples of blood/ and the excellent 
characteristics of the hybrids obtained.
There still remains the problem of establishing 
lines of pre-defined specificity. At first sight the 
results from this study do not look very encouraging. No 
human immunoglobulin-secreting hybrids were derived from 
autoimmune patients which produced antibodies with 
specificities anticipated from the data on the patients* 
sera. However/ there are a number of points to take into 
consideration. All fusions with B cells derived from 
autoimmune patients were performed without EBV 
transformation. The 679 human MCA screened may just have 
been too small a sample. This can easily be determined by 
performing another series of fusions following EBV 
transformation. This would allow many thousands of 
hybrids to be screened from each blood sample.
Another problem concerns the detection of MCA 
to the AChR. The raising of rodent MCA to the human AChR 
in this department has also proved to be extremely 
difficult. Although mice can be immunised to produce high 
serum antibody titres/ no MCA-secreting hybrids were 
identified after screening nearly 1000 hybrids using a 
RIA analagous to the assay used in this study. No 
problems were encountered/ however using AChR from the 
electric organ of Torpedo Electrophorus as the immunogen
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and target in the assay. Thus there may have been a 
problem peculiar to the assay using human AChR for 
screening MCA (as discussed in Chapter 6). More 
confidence could be placed in the results of the 
remaining 220 MCA from SLE patients. However/ this 
represents a very small sample from which to draw 
conclusions about the feasibility of obtaining monoclonal 
autoantibodies.
The choice of autoimmune patients as "naturally 
immunised" subjects may not have been an appropriate 
model to evaluate the production of human MCA. There 
remains the possibility that the relevant antigen 
specific B cells are not activated or mobilised in the 
same way in autoimmune patients as following deliberate 
immunisation. Once again/ this can be determined by 
screening a far greater number of hybrids/ or by using 
lymphocytes obtained from other lymphoid tissue.
EBV has been shown in other studies to be 
clearly capable of activating and transforming 
circulating B cells with specificities to administered 
antigens (Kozbor ^t a_l. 1979/ Zurawski eit a_l. 1978/ 
Crawford et^  al^ . 1983/ Yoshie and Ono 1980) and to 
autoantigens (Steinitz e£ al^ . 1980/ Kamo et^  al^ . 1981). In 
view of the high fusion frequency of EBV transformed 
cells with X63/ the rescue of specific antibody-secreting 
cells following transformation should be straightforward. 
Thus the production of human MCA of pre-defined 
specificity from PBL/ following EBV transformation and
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fusion looks extremely promising.
The most suprising finding concerning the MCA 
made in this study was the high percentage of MCA which 
demonstrated binding to intermediate filaments. Although 
the presence of serum autoantibodies to intermediate 
filaments has been described in SLE/ they were not found 
in the sera of the patients studied here. Furthermore/ 
similarly high proportions of anti-intermediate filament 
MCA were made following fusions with MG PBL/ normal PBL 
and normal/ EBV transformed tonsil B cells. Their 
frequent occurence cannot therefore be associated with 
overt disease. B cells have been demonstrated/ in 
non-autoimmune subjects/ which synthesise antibodies to 
autoantigens. It may be that the fusion process (with or 
without EBV transformation) rescues quiescent B cells/ 
and thus the MCA made reflect the antibody potential of 
circulating B cells rather than the serum antibodies 
synthesised by mature plasma cells. The normally 
controlled autoreactivity present in us all is thus 
revealed. The fusion process may have something in common 
with the polyclonal activation of B cells. The high 
percentage of anti-intermediate filament MCA found is 
consistent with the frequent demonstration of 
anti-intermediate filament antibodies made following 
stimulation of B cells with PCA both iji vitro and in 
vivo. The presence of anti-intermediate filament 
antibodies in many diverse infectious and autoimmune 
diseases may also a consequence of polyclonal activation
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known to occur in these situations. It is difficult 
however/ to understand why such a high percentage of B 
cells are present which produce anti-intermediate 
filament antibodies. It is not convincing to explain this 
in terms of a physiological function for such antibodies. 
It is also difficult to imagine the fusion process/ EBV 
transformation and polyclonal activation all selecting 
for B cells making antibodies of this specificity. That 
these antibodies may not be binding to intermediate 
filaments by conventional antibody-antigen interactions 
is a distinct possibility. There is evidence which 
supports this idea. Many rodent MCA have been described 
which have been raised to very different molecules and 
then found to also bind to intermediate filaments. It 
would seem that many MCA with different antigen binding 
sites share a common feature of being able to bind 
intermediate filaments. The nature of the binding of 
these MCA needs to be examined by using immunoglobulin 
fragments rather than whole molecules/ looking at fine 
specificities/ and by comparison with antibodies raised 
by deliberate cross-species immunisation with 
intermediate filaments.
Although the findings of this study throw no 
light on the autoimmune diseases SLE and MG/ the MCA 
reactive with intermediate filaments may contribute to a 
better understanding of the common occurence of such 
antibodies in a number of different disease situations. 
The efficient technique developed here of making human
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MCA promises to finally bring human MCA technology onto a 
level with that of its rodent counterpart. The 
contributions of human MCA to the understanding of human 
immune responses and the understanding and treatment of 
human disease/ promise to be equally as exciting as the 
revolution brought about by rodent MCA technology.
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APPENDIX
The detection of MCA to nuclear and cytoplasmic 
antigens by ELISA.
Culture supernatants were judged positive or negative 
by comparison to culture supernatants containing 
irrelevant monoclonal antibodies. These negative 
controls gave less than 0.2 O.D. units above the 
background shown by wells receiving no immunoglobulin, 
even after 2 hours of substrate incubation. The culture 
supernatants judged to be negative gave O.D. values 
between 0.0 and 0.3 above the irrelevant MCA controls. 
The four culture supernatants judged to be positive 
gave optical densities between 0.8 and 1.6 above the 
irrelevant MCA controls after 2 hours of substrate 
incubation. It should be noted that after this length 
of incubation, the normal human sera controls (diluted 
1:1000) gave O.D. values in the same range as these 
four positives.
